Respiratory system disorder
MONDO:0005087A non-neoplastic or neoplastic disorder that affects the respiratory system. Representative examples include pneumonia, chronic obstructive pulmonary disease, pulmonary failure, lung adenoma, lung carcinoma, and tracheal carcinoma.
Also known as: disease of respiratory system, disease or disorder of respiratory system, disorder of respiratory system, respiratory disease, respiratory disorder, respiratory system disease, respiratory system disease or disorder, respiratory system disorder
11330 clinical trials for this condition and its sub-types, 153 tagged with Respiratory system disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Respiratory system disorder
-
Lower respiratory tract disorder 21 trials · 8,268 incl. sub-types
5 sub-types
- Lung disorder 264 trials · 7,374 incl. sub-types Sub-types →
- Tracheal disorder 6 trials · 1,148 incl. sub-types Sub-types →
- Bronchial disorder 19 trials · 1,049 incl. sub-types Sub-types →
- Pleural disorder 17 trials · 186 incl. sub-types Sub-types →
- Tracheobronchitis 5 trials · 58 incl. sub-types Sub-types →
-
Respiratory system cancer 6 trials · 4,676 incl. sub-types
9 sub-types
- Lung cancer 1,252 trials · 4,084 incl. sub-types Sub-types →
- Pharynx cancer 12 trials · 512 incl. sub-types Sub-types →
- Larynx cancer 41 trials · 127 incl. sub-types Sub-types →
- Pleural cancer 10 trials · 85 incl. sub-types Sub-types →
- Bronchus cancer 3 trials · 26 incl. sub-types Sub-types →
- Paranasal sinus cancer 4 trials · 25 incl. sub-types Sub-types →
- Nasal cavity cancer 5 trials · 14 incl. sub-types Sub-types →
- SMARCA4-deficient sarcoma of thorax 8 trials
- Tracheal cancer 0 trials · 1 incl. sub-types Sub-types →
-
Respiratory tract neoplasm 32 trials · 4,590 incl. sub-types
8 sub-types
- Lung neoplasm 1,417 trials · 4,185 incl. sub-types Sub-types →
- Nasopharyngeal neoplasm 37 trials · 230 incl. sub-types Sub-types →
- Laryngeal neoplasm 74 trials · 140 incl. sub-types Sub-types →
- Pleural neoplasm 5 trials · 100 incl. sub-types Sub-types →
- Bronchial neoplasm 20 trials · 38 incl. sub-types Sub-types →
- Nasal cavity neoplasm 1 trial · 15 incl. sub-types Sub-types →
- SMARCA4-deficient sarcoma of thorax 8 trials
- Trachea neoplasm 2 trials · 5 incl. sub-types Sub-types →
-
Upper respiratory tract disorder 5 trials · 1,938 incl. sub-types
10 sub-types
- Tracheal disorder 6 trials · 1,148 incl. sub-types Sub-types →
- Nasopharyngeal disorder 1 trial · 270 incl. sub-types Sub-types →
- Laryngeal disorder 45 trials · 263 incl. sub-types Sub-types →
- Nasal cavity disorder 3 trials · 239 incl. sub-types Sub-types →
- Pharyngitis 38 trials · 47 incl. sub-types Sub-types →
- Tonsillitis 25 trials · 29 incl. sub-types Sub-types →
- Adenoid hypertrophy 24 trials
- Epiglottitis 1 trial Sub-types →
- Acute laryngopharyngitis 0 trials
- Uvulitis 0 trials
-
Respiratory tract infectious disorder 184 trials · 1,400 incl. sub-types
14 sub-types
- Pneumonia 336 trials · 632 incl. sub-types Sub-types →
- Viral respiratory tract infection 49 trials · 600 incl. sub-types Sub-types →
- Fungal lung infectious disease 6 trials · 59 incl. sub-types Sub-types →
- Pulmonary non-tuberculous mycobacterial infection 49 trials
- Streptococcal sore throat 10 trials
- Pleural tuberculosis 7 trials Sub-types →
- Tracheitis 2 trials · 7 incl. sub-types Sub-types →
- Lung abscess 3 trials
- Pneumonic plague 3 trials
- Tuberculous fibrosis of lung 3 trials
- Laryngeal diphtheria 0 trials
- Laryngeal tuberculosis 0 trials
- Nasopharyngeal diphtheria 0 trials
- Silicotuberculosis 0 trials
-
Sleep apnea syndrome 226 trials · 640 incl. sub-types
2 sub-types
- Obstructive sleep apnea syndrome 554 trials · 555 incl. sub-types Sub-types →
- Central sleep apnea syndrome 22 trials · 24 incl. sub-types Sub-types →
-
Disorder of pharynx 3 trials · 618 incl. sub-types
10 sub-types
- Pharynx cancer 12 trials · 512 incl. sub-types Sub-types →
- Neoplasm of oropharynx 3 trials · 289 incl. sub-types Sub-types →
- Nasopharyngeal disorder 1 trial · 270 incl. sub-types Sub-types →
- Neoplasm of hypopharynx 0 trials · 101 incl. sub-types Sub-types →
- Tonsillitis 25 trials · 29 incl. sub-types Sub-types →
- Takayasu arteritis 28 trials
- Tonsil neoplasm 0 trials · 9 incl. sub-types Sub-types →
- Peritonsillar abscess 4 trials
- Epiglottitis 1 trial Sub-types →
- Oropharyngeal anthrax 0 trials
-
Cystic fibrosis 296 trials
1 sub-type
-
Allergic respiratory disease 2 trials · 232 incl. sub-types
4 sub-types
- Allergic rhinitis 105 trials · 151 incl. sub-types Sub-types →
- Allergic asthma 42 trials Sub-types →
- Hypersensitivity pneumonitis 27 trials · 32 incl. sub-types Sub-types →
- Allergic bronchopulmonary aspergillosis 15 trials Sub-types →
-
Paranasal sinus disorder 13 trials · 173 incl. sub-types
7 sub-types
- Sinusitis 45 trials · 140 incl. sub-types Sub-types →
- Paranasal sinus neoplasm 5 trials · 30 incl. sub-types Sub-types →
- Maxillary sinus cholesteatoma 0 trials
- Polyp of ethmoidal sinus 0 trials
- Polyp of frontal sinus 0 trials
- Polyp of maxillary sinus 0 trials
- Polyp of sphenoidal sinus 0 trials
-
Perinatal asphyxia 160 trials
-
Pulmonary tuberculosis 112 trials · 115 incl. sub-types
3 sub-types
- Tuberculous fibrosis of lung 3 trials
- Primary pulmonary tuberculosis 0 trials
- Silicotuberculosis 0 trials
-
Bronchopulmonary dysplasia 99 trials
-
Diaphragm disorder 27 trials · 92 incl. sub-types
5 sub-types
- Congenital diaphragmatic hernia 46 trials Sub-types →
- Respiratory paralysis 20 trials
- Diaphragmatic eventration 3 trials
- Diaphragmatic malformation 1 trial
- Diaphragmitis 0 trials
-
Altitude sickness 54 trials · 56 incl. sub-types
2 sub-types
- Acute mountain sickness 7 trials
- Chronic mountain sickness 3 trials
-
Alpha 1-antitrypsin deficiency 45 trials
-
Pertussis 42 trials
-
Primary ciliary dyskinesia 34 trials
59 sub-types
- Primary ciliary dyskinesia 1 6 trials
- CFAP46-related primary ciliary dyskinesia 0 trials
- Stromme syndrome 0 trials
- Ciliary discoordination due to random ciliary orientation 0 trials
- Ciliary dyskinesia with defective radial spokes 0 trials
- Ciliary dyskinesia with excessively long cilia 0 trials
- Ciliary dyskinesia with transposition of ciliary microtubules 0 trials
- Ciliary dyskinesia, primary, 36, X-linked 0 trials
- Ciliary dyskinesia, primary, 37 0 trials
- Ciliary dyskinesia, primary, 38 0 trials
- Ciliary dyskinesia, primary, 39 0 trials
- Ciliary dyskinesia, primary, 40 0 trials
- Ciliary dyskinesia, primary, 41 0 trials
- Ciliary dyskinesia, primary, 42 0 trials
- Ciliary dyskinesia, primary, 43 0 trials
- Ciliary dyskinesia, primary, 44 0 trials
- Ciliary dyskinesia, primary, 45 0 trials
- Ciliary dyskinesia, primary, 46 0 trials
- Ciliary dyskinesia, primary, 47, and lissencephaly 0 trials
- Ciliary dyskinesia, primary, 48, without situs inversus 0 trials
- Ciliary dyskinesia, primary, 49, without situs inversus 0 trials
- Ciliary dyskinesia, primary, 50 0 trials
- Ciliary dyskinesia, primary, 51 0 trials
- Ciliary dyskinesia, primary, 52 0 trials
- Ciliary dyskinesia, primary, 53 0 trials
- Ciliary dyskinesia, primary, 54 0 trials
- Primary ciliary dyskinesia 10 0 trials
- Primary ciliary dyskinesia 11 0 trials
- Primary ciliary dyskinesia 12 0 trials
- Primary ciliary dyskinesia 13 0 trials
- Primary ciliary dyskinesia 14 0 trials
- Primary ciliary dyskinesia 15 0 trials
- Primary ciliary dyskinesia 16 0 trials
- Primary ciliary dyskinesia 17 0 trials
- Primary ciliary dyskinesia 18 0 trials
- Primary ciliary dyskinesia 19 0 trials
- Primary ciliary dyskinesia 2 0 trials
- Primary ciliary dyskinesia 20 0 trials
- Primary ciliary dyskinesia 21 0 trials
- Primary ciliary dyskinesia 22 0 trials
- Primary ciliary dyskinesia 23 0 trials
- Primary ciliary dyskinesia 24 0 trials
- Primary ciliary dyskinesia 25 0 trials
- Primary ciliary dyskinesia 26 0 trials
- Primary ciliary dyskinesia 27 0 trials
- Primary ciliary dyskinesia 28 0 trials
- Primary ciliary dyskinesia 29 0 trials
- Primary ciliary dyskinesia 3 0 trials
- Primary ciliary dyskinesia 30 0 trials
- Primary ciliary dyskinesia 32 0 trials
- Primary ciliary dyskinesia 33 0 trials
- Primary ciliary dyskinesia 34 0 trials
- Primary ciliary dyskinesia 35 0 trials
- Primary ciliary dyskinesia 4 0 trials
- Primary ciliary dyskinesia 5 0 trials
- Primary ciliary dyskinesia 6 0 trials
- Primary ciliary dyskinesia 7 0 trials
- Primary ciliary dyskinesia 8 0 trials
- Primary ciliary dyskinesia 9 0 trials
-
Severe acute respiratory syndrome 32 trials
-
Infantile apnea 5 trials · 22 incl. sub-types
1 sub-type
- Apnea of prematurity 20 trials
-
Recurrent respiratory papillomatosis 8 trials · 9 incl. sub-types
1 sub-type
- Laryngeal papillomatosis 1 trial
-
Respiratory or thoracic malformation 0 trials · 9 incl. sub-types
1 sub-type
- Thoracic malformation 1 trial · 9 incl. sub-types Sub-types →
-
Respiratory system benign neoplasm 1 trial · 8 incl. sub-types
15 sub-types
- Benign laryngeal neoplasm 1 trial · 2 incl. sub-types Sub-types →
- Benign neoplasm of trachea 0 trials · 2 incl. sub-types Sub-types →
- Lung benign neoplasm 1 trial · 2 incl. sub-types Sub-types →
- Benign neoplasm of nasal cavity 1 trial Sub-types →
- Benign neoplasm of ethmoidal sinus 0 trials Sub-types →
- Benign neoplasm of frontal sinus 0 trials Sub-types →
- Benign neoplasm of hypopharynx 0 trials Sub-types →
- Benign neoplasm of maxillary sinus 0 trials Sub-types →
- Benign neoplasm of nasopharynx 0 trials
- Benign neoplasm of oropharynx 0 trials
- Benign neoplasm of pleura 0 trials Sub-types →
- Benign neoplasm of sphenoidal sinus 0 trials Sub-types →
- Benign neoplasm of tonsil 0 trials Sub-types →
- Endobronchial lipoma 0 trials
- Paranasal sinus Schneiderian papilloma 0 trials Sub-types →
-
Pulmonary hypoplasia 7 trials
-
Reactive airway disease 5 trials
-
2 sub-types
-
5 sub-types
-
Young syndrome 2 trials
-
Diffuse alveolar hemorrhage 2 trials
-
Plastic bronchitis 2 trials
-
Middle East respiratory syndrome 1 trial
-
Bronchogenic cyst 1 trial
-
3 sub-types
-
16q24.1 microdeletion syndrome 0 trials
-
IgG4-related mediastinitis 0 trials
-
Mounier-Kuhn syndrome 0 trials
-
Siegler-Brewer-Carey syndrome 0 trials
-
Williams-Campbell syndrome 0 trials
-
Acinar dysplasia 0 trials
3 sub-types
-
Bronchiectasis and nasal polyposis 0 trials
-
Congenital bronchobiliary fistula 0 trials
-
Eosinophilic granuloma 0 trials
1 sub-type
-
Isolated left bronchial isomerism 0 trials
-
Laryngo-onycho-cutaneous syndrome 0 trials
-
Mucopolysaccharidosis-plus syndrome 0 trials
-
Pulmonary agenesis 0 trials
-
Staphylococcal necrotizing pneumonia 0 trials
-
Tracheal agenesis 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 4219 trials in this tab.
-
Cell therapy HS-IT101 put to the test against advanced lung cancer
Cure Recruiting nowResearchers are testing an experimental cell-based immunotherapy called HS-IT101 in adults with advanced non-small cell lung cancer that has worsened after at least one standard treatment. The small Phase Ib trial enrolls about 12 people. Participants receive chemotherapy drugs t…
Phase 1 • Sponsor: Hangzhou Huasai Biomedicine Co., Ltd. • Aim: Cure
Last updated Oct 16, 2026 00:00 UTC
-
A Patient's own immune cells, grown in the lab, tested against advanced lung cancer
Cure Recruiting nowResearchers are testing an experimental cell therapy called HS-IT101 in people with advanced non-small cell lung cancer. The treatment uses tumor-infiltrating lymphocytes (TILs), immune cells taken from the patient's own tumor, multiplied in the lab, and given back. Before receiv…
Phase 1 • Sponsor: Hangzhou Huasai Biomedicine Co., Ltd. • Aim: Cure
Last updated Oct 16, 2026 00:00 UTC
-
Breathable antifungal could boost pneumonia recovery
Cure Recruiting nowResearchers test whether adding daily inhaled caspofungin to standard antifungal therapy helps adults with Pneumocystis pneumonia recover faster. The trial enrolls 100 adults receiving oxygen or breathing support and standard antifungal drugs. Participants receive either the inha…
Phase 1/2 • Sponsor: University Hospital, Tours • Aim: Cure
Last updated Oct 11, 2026 00:00 UTC
-
One shot, two viruses: vaccine aims to shield older adults from RSV and HMPV
Vaccine Recruiting nowResearchers are testing a single injection vaccine designed to protect adults 60 and older from two respiratory viruses: RSV and HMPV. The trial plans to enroll about 8,000 participants who will randomly receive either the vaccine or a placebo. Scientists will track who develops …
Phase 2 • Sponsor: Sanofi • Aim: Vaccine
Last updated Oct 20, 2026 06:00 UTC
-
New universal flu vaccine enters human testing
Vaccine Recruiting nowThis study tests an experimental flu vaccine called BPL-1357, given as a shot or nasal spray, to see if it is safe and can protect against multiple flu types. About 129 healthy adults aged 18-55 will receive the vaccine or a placebo, then be exposed to a flu virus in a controlled…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Oct 20, 2026 06:00 UTC
-
Can a booster RSV shot shield the immunocompromised?
Vaccine Recruiting nowThis phase 3 trial is investigating whether giving a repeat dose of the RSVpreF vaccine to immunocompromised adults is safe and triggers a strong immune response. Participants, aged 18 and older, will receive one shot and be monitored for about a year. The study aims to find the …
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Oct 16, 2026 00:00 UTC
-
One shot, two viruses: could a combined vaccine shield seniors from RSV and HMPV?
Vaccine Recruiting nowThis trial is testing an experimental vaccine designed to protect against two respiratory viruses at once: RSV and HMPV. The study involves about 2,400 adults aged 60 and older, who will receive one of several dose levels of the vaccine, a placebo, or a control vaccine. Researche…
Phase 1/2 • Sponsor: Sanofi • Aim: Vaccine
Last updated Oct 16, 2026 00:00 UTC
-
MRNA flu shot put to the test in 3,000 adults
Vaccine Recruiting nowResearchers are testing an mRNA-based seasonal influenza vaccine in adults aged 18 to 64. The trial compares the immune response and side effects of the mRNA vaccine against standard flu vaccines. About 3,000 participants receive one injection in the upper arm and are followed fo…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Oct 11, 2026 00:00 UTC
-
New nasal vaccine aims to protect kids from RSV
Vaccine Recruiting nowThis study tests a new nasal spray vaccine (BLB-201) to prevent RSV, a common virus that can cause serious breathing problems in young children. About 137 infants and children aged 8 to 59 months will receive either the vaccine or a placebo. The goal is to check if the vaccine is…
Phase 1/2 • Sponsor: Blue Lake Biotechnology Inc. • Aim: Vaccine
Last updated Oct 11, 2026 00:00 UTC
-
Pfizer tests RSV vaccine aimed at older adults
Vaccine Recruiting nowResearchers are testing an RSV vaccine in healthy adults aged 60 and older to see how safe it is and how well it triggers an immune response. The trial enrolls about 600 people in China and the United States. In China, participants receive either the vaccine or a placebo; in the …
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Oct 11, 2026 00:00 UTC
-
Can a pneumonia vaccine protect the most vulnerable children?
Vaccine Recruiting nowThis study tests whether a pneumococcal vaccine (Pneumosil) can produce a strong immune response in children aged 6-59 months who are hospitalised with severe acute malnutrition. Half the children will receive the pneumococcal vaccine, and the other half will receive a typhoid va…
Phase 4 • Sponsor: Nick Fancourt • Aim: Vaccine
Last updated Oct 10, 2026 00:00 UTC
-
Texts vs. manuals: new trial aims to help rural cancer survivors kick the habit
Disease control Recruiting nowThis study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Could a pill replace CPAP for sleep apnea? large study tests three treatments Head-to-Head
Disease control Recruiting nowThis study compares three treatments for obstructive sleep apnea: positive airway pressure (CPAP), a dental device that moves the jaw forward, and a combination of two medications (atomoxetine and oxybutynin). About 2,400 adults with sleep apnea will be randomly assigned to one o…
Phase 4 • Sponsor: Sairam Parthasarathy • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Can a pill replace the liquid? testing a new form of cystic fibrosis drug
Disease control Recruiting nowResearchers are testing whether a tablet form of the experimental cystic fibrosis drug VX-581 gets into the bloodstream as well as the liquid form. Sixteen healthy adults will take both forms in a randomized order, and researchers will measure drug levels in their blood over time…
Phase 1 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New pill targets Hard-to-Treat lung cancer mutation
Disease control Recruiting nowThis trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Radiation before pills may slow lung cancer progression
Disease control Recruiting nowThis study tests whether giving radiation to the main lung tumor before starting targeted therapy pills can delay cancer growth in people with advanced, gene-mutated non-small cell lung cancer. About 34 adults who have not yet had treatment will receive radiation to the primary l…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New vaccine could help throat cancer patients avoid radiation
Disease control Recruiting nowThis phase 2 trial tests whether adding an experimental vaccine (PRGN-2009) to standard chemotherapy can improve outcomes for people with newly diagnosed HPV-related throat cancer, potentially allowing them to skip radiation. About 70 adults will receive either chemo alone or che…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New shot could tame COPD Flare-Ups for those with eosinophilic lung disease
Disease control Recruiting nowThis study tests a new injectable drug called lunsekimig in about 942 adults aged 40-80 with COPD that is not well controlled, especially those with a type linked to high eosinophils (a kind of white blood cell). Participants will receive either the drug or a placebo for about 48…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental oral drug called FMC-376 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The trial has three parts: first, finding the safest dose; then, checking how well th…
Phase 1/2 • Sponsor: Frontier Medicines Corporation • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Can a One-Two punch of immunotherapy and radiation wipe out head and neck tumors before surgery?
Disease control Recruiting nowThis phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab with a short course of high-dose radiation, with or without additional radiation to nearby lymph nodes, can shrink or eliminate head and neck tumors before surgery. Adults with resectable squamou…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Could an immunotherapy drug keep early lung cancer from returning?
Disease control Recruiting nowThis phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New pill-chemo combo takes on hard-to-treat cancers
Disease control Recruiting nowThis study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Targeted radiation after lung cancer surgery aims to stop return
Disease control Recruiting nowThis study tests whether adding a precise type of radiation therapy (I²-PORT) after lung cancer surgery can help prevent the cancer from coming back. Participants have non-small cell lung cancer with remaining cancer in lymph nodes after initial treatment. The trial compares stan…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New hope for lung cancer: targeted drug telisotuzumab vedotin faces off against chemo
Disease control Recruiting nowThis phase 3 trial compares a new targeted drug, telisotuzumab vedotin, to the standard chemotherapy docetaxel in adults with a specific type of advanced non-small cell lung cancer that has a high level of a protein called c-Met. About 698 participants worldwide will receive eith…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New combo therapy aims to control returning throat cancer
Disease control Recruiting nowThis study tests a two-step treatment for people whose nasopharyngeal cancer has come back after initial treatment. First, patients receive a targeted drug (MRG003) plus an immunotherapy (PD-1) for six weeks. Then, they take a chemotherapy pill (capecitabine) with the immunothera…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New inhaled drug aims to keep bronchiectasis patients Flare-Up free
Disease control Recruiting nowThis study tests an inhaled medicine called CSL787 in adults with non-cystic fibrosis bronchiectasis, a lung condition that causes frequent infections and breathing problems. The goal is to see if CSL787 can delay the time until a person's next lung flare-up (exacerbation) compar…
Phase 2 • Sponsor: CSL Behring • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New implant aims to release trapped air in lungs of COPD patients
Disease control Recruiting nowThis study tests a permanent implant called the Apreo BREATHE Airway Scaffold in up to 250 adults with COPD and emphysema who still feel short of breath despite standard treatments. The implant is designed to prop open airways and release trapped air to improve breathing. Researc…
Sponsor: Apreo Health, Inc. • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New antibody combo aims to boost lung cancer treatment response
Disease control Recruiting nowThis study tests whether adding the experimental drug visugromab to standard chemotherapy and immunotherapy can shrink tumors better than standard treatment alone in people with advanced non-squamous lung cancer that has not been treated before. About 107 adults with newly diagno…
Phase 2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Can a Two-Drug combo keep Limited-Stage lung cancer at bay?
Disease control Recruiting nowThis phase 2 trial tests whether combining an experimental drug called SHR-7787 with the immunotherapy adebrelimab can help people with limited-stage small cell lung cancer. The study enrolls adults aged 18 to 75 whose cancer has not progressed after standard chemotherapy and rad…
Phase 2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Could treating sleep apnea help veterans beat PTSD and addiction?
Disease control Recruiting nowThis study looks at whether treating obstructive sleep apnea (OSA) early with a positive airway pressure (PAP) device can improve outcomes for veterans with both PTSD and substance use disorder. About 194 veterans in a residential treatment program will either receive PAP therapy…
Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
RNA editing drug hopes to fix genetic flaw in rare lung and liver disease
Disease control Recruiting nowThis early-phase trial tests an experimental drug called WVE-006 in 24 people with a severe form of alpha-1 antitrypsin deficiency (Pi*ZZ). The drug is designed to edit RNA to help the body produce a working version of the protective protein. The main goal is to check safety, but…
Phase 1/2 • Sponsor: Wave Life Sciences USA, Inc. • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Engineered immune cells take on tough lung cancer
Disease control Recruiting nowThis study tests a new treatment called DJI136, which uses a patient's own immune cells engineered to target a protein (DLL3) found on small cell lung cancer cells. The trial enrolls 80 adults with extensive-stage small cell lung cancer whose disease has progressed after standard…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Radioactive drug takes on standard therapy in lung cancer trial
Disease control Recruiting nowThis phase II trial tests whether a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced bronchial neuroendocrine tumors (a type of lung cancer). The radioactive drug targets a protein on tumor cells and delivers ra…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Engineered immune cells take aim at deadly lung cancer
Disease control Recruiting nowThis early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New biologic ZG006 targets tough lung and neuroendocrine cancers
Disease control Recruiting nowThis study tests a new biologic drug called ZG006 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial has two parts: first, finding a safe dose (Phase 1), then testing how well it shrinks tumors (Phase 2). About 265 participants will receive ZG00…
Phase 1/2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Could an immune booster keep early lung cancer from returning?
Disease control Recruiting nowThis phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New mRNA vaccine combo aims to prevent lung cancer recurrence in High-Risk patients
Disease control Recruiting nowThis phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New TB cocktails aim to speed up recovery
Disease control Recruiting nowThis study tests new combinations of drugs for adults with lung tuberculosis (TB). The goal is to see if these new regimens work faster and are safer than the current standard treatment. About 315 participants will receive either an experimental drug combo or the usual care for 8…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New combo therapy aims to keep lung cancer from returning after surgery
Disease control Recruiting nowThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after surgery can help prevent non-small cell lung cancer from coming back. About 1,210 people with stage II to IIIB lung cancer will receive either chemo plus pembrolizumab toge…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
Could a nebulizer beat an inhaler for COPD symptom relief?
Disease control Recruiting nowThis trial asks whether giving COPD medication through a nebulizer works better than a dry powder inhaler. It enrolls adults over 40 with COPD symptoms and significant air trapping. Participants receive either a nebulizer or inhaler treatment, and researchers compare changes in l…
Phase 4 • Sponsor: University of Tennessee Graduate School of Medicine • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New hope for Hard-to-Treat lung cancer: targeted drug combo trial launches
Disease control Recruiting nowThis study is testing new drugs called RAS(ON) inhibitors for people with advanced non-small cell lung cancer that has a RAS mutation. The goal is to see if these drugs are safe and can shrink tumors or slow the cancer's growth. About 616 adults who have already tried standard tr…
Phase 1/2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Oct 20, 2026 06:00 UTC
-
New hope for lung scarring? drug trial aims to slow breathing decline
Disease control Recruiting nowThis study tests two doses of an experimental drug, zampilimab, against a placebo in 240 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The main goal is to see if the drug can improve lung function over 24 weeks, with an …
Phase 2 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New hope for tough lung cancer: targeted drug ZL-1310 enters final testing
Disease control Recruiting nowThis Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…
Phase 3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New pill aims to slow lung scarring in IPF patients
Disease control Recruiting nowThis phase 2 trial tests an oral drug called PIPE-791 in 324 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either a low or high dose of PIPE-791 or a placebo daily for several months. The main goal is t…
Phase 2 • Sponsor: Contineum Therapeutics • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Could a cholesterol drug boost lung cancer treatment before surgery?
Disease control Recruiting nowThis phase 2 trial tests whether adding the cholesterol-lowering drug alirocumab to standard chemotherapy and immunotherapy (cemiplimab) before surgery helps eliminate more cancer in people with stage 1B-3A non-small cell lung cancer. About 126 participants will be randomly assig…
Phase 2 • Sponsor: Duke University • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Umbilical cord stem cells tested as lung disease therapy
Disease control Recruiting nowResearchers test whether intravenous infusions of donated umbilical cord or placental stem cells are safe for people with pulmonary diseases such as asthma and COPD. The trial enrolls 20 adults with a diagnosed lung condition. Participants receive the stem cell infusions, and doc…
Phase 1 • Sponsor: The Foundation for Orthopaedics and Regenerative Medicine • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Can fewer radiation sessions be safer for lung cancer?
Disease control Recruiting nowThis trial is testing two different radiation schedules for people with peripheral lung cancer or a single lung metastasis. One group receives the standard five-session treatment, while the other gets an experimental three-session approach. The goal is to see if the shorter sched…
Phase 2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Can an ancient herbal mix stall scarring lung disease?
Disease control Recruiting nowResearchers are testing whether Jin-shui Huan-xian Granules, a traditional Chinese herbal formula, can slow the loss of lung function in people with idiopathic pulmonary fibrosis (IPF). The trial enrolls 384 adults aged 40 to 85 with IPF who also have specific patterns of fatigue…
Sponsor: Henan University of Traditional Chinese Medicine • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Smart inhalers and video visits could transform Kids' asthma care
Disease control Recruiting nowThis study explores whether using connected inhalers that track medication use, combined with video doctor visits when problems arise, can manage childhood asthma as well as standard in-person care. Fifty children aged 4 to 12 with asthma will take part for 8 months. Half will us…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New hope for lung cancer: drug cocktail trial launches
Disease control Recruiting nowThis phase 2 trial is testing whether adding a targeted drug called HER3-DXd to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced non-small cell lung cancer that hasn't been treated yet. About 90 participants will receive different combinations…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New drug combo targets rare bladder cancer
Disease control Recruiting nowThis phase II trial tests two drugs, lurbinectedin and avelumab, in people with a rare and aggressive bladder cancer called small cell carcinoma. Participants who have already had a drug like avelumab will receive only lurbinectedin; others will get both. The study aims to see if…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New combo therapy aims to control returning lung cancer in targeted patients
Disease control Recruiting nowThis study is for people with a specific type of lung cancer (EGFR-mutant) that has spread to other parts of the body after they finished a previous treatment (osimertinib). The goal is to see if combining osimertinib with chemotherapy can help control the cancer for longer. Abou…
Phase 4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Can a higher dose slow lung damage in Alpha-1 patients?
Disease control Recruiting nowThis study tests whether higher doses of the drug Respreeza/Zemaira can slow lung damage better than the standard dose in adults with emphysema caused by Alpha-1 antitrypsin deficiency. About 270 participants will receive weekly IV infusions for 3 years. The goal is to find the o…
Phase 4 • Sponsor: CSL Behring • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Recruiting nowThis early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…
Phase 1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Radioactive missile aims at Cancer's c-MET switch
Disease control Recruiting nowResearchers are testing a new targeted radioligand therapy called [225Ac]Ac-FL-261 in people with advanced solid tumors that overexpress a protein called c-MET. The therapy pairs a radioactive particle with a molecule that seeks out c-MET, aiming to deliver radiation directly to …
Phase 1/2 • Sponsor: Full-Life Technologies UK Limited • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Engineered immune cells take on tough cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called ML261 for people with advanced small cell lung cancer or certain neuroendocrine cancers that have not responded to standard treatments. ML261 is made from a patient's own immune cells, which are modified in a lab to better recog…
Phase 1 • Sponsor: Moonlight Bio, Inc • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Could early heart support protect Brain-Injured newborns?
Disease control Recruiting nowSome newborns with HIE, a brain injury from lack of oxygen at birth, also develop heart problems. This pilot trial tests whether starting a heart medication called dobutamine early, before heart failure signs appear, is feasible and safe. Forty babies receiving cooling therapy wi…
Phase 2 • Sponsor: University of Alberta • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New inhaled drug aims to fight deadly lung scarring
Disease control Recruiting nowThis Phase 2 trial tests an experimental inhaled medication called LTI-03 in about 120 people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes scarring and breathing difficulty. Participants will inhale LTI-03 or a placebo twice daily for 24 weeks.…
Phase 2 • Sponsor: Rein Therapeutics • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Smart drug targets two cancer weaknesses at once
Disease control Recruiting nowThis trial tests a new drug called AN4035 in people with advanced solid tumors that have RAS mutations and high levels of the CEACAM5 protein. The drug is designed to seek out cancer cells carrying CEACAM5 and deliver a payload that blocks RAS, a key driver of cancer growth. The …
Phase 1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Can a health coach at home keep COPD patients out of the hospital?
Disease control Recruiting nowThis study tests whether personalized home-based coaching can help people with COPD better manage their symptoms and avoid hospital visits. Researchers will enroll 300 adults from diverse backgrounds in New York City. Participants will receive support from health coaches, includi…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Can dupilumab keep COPD patients out of the hospital?
Disease control Recruiting nowThis study tests whether adding dupilumab to standard COPD treatment can prevent another flare-up or hospital stay within 90 days. About 754 adults who were recently hospitalized for a COPD exacerbation will receive either dupilumab or a placebo. The goal is to see if the drug re…
Phase 4 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New COPD drug tozorakimab moves to Long-Term safety check
Disease control Recruiting nowThis study is testing the long-term safety of a drug called tozorakimab in people with chronic obstructive pulmonary disease (COPD) who have had flare-ups in the past. About 82 participants who completed earlier studies will receive tozorakimab and be monitored for side effects. …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Could CAR t cells tame scleroderma? new trial launches
Disease control Recruiting nowThis early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…
Phase 2/3 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Lifeline for lung patients: TPIP access extended
Disease control Expanded accessThis study offers continued access to the inhaled drug TPIP for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD) who have already completed a related study. Participants must have successfully finished prior …
Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New combo aims to outsmart lung Cancer's growth signals
Disease control Recruiting nowThis Phase III trial is testing whether adding bevacizumab to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 300 people with stage IIIB or IV disease will be randomly assigned to receive either the combination or osimertini…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
One-Time gene therapy could shield lungs in rare disease
Disease control Recruiting nowThis early-stage study tests a gene therapy for people with alpha-1 antitrypsin deficiency, a condition that can damage the lungs. The treatment is given once through a vein and aims to produce a special protein that protects the lungs. Researchers will check safety and measure p…
Phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Experimental drug aims to tame severe asthma and COPD attacks
Disease control Recruiting nowThis trial tests a single dose of rademikibart, given intravenously, as an add-on treatment for people hospitalized with an acute asthma or COPD flare-up who also have type 2 inflammation. The study includes 40 adults and measures how well the drug improves lung function and cont…
Phase 2 • Sponsor: Connect Biopharm LLC • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Could clearing lung bacteria boost cancer treatment?
Disease control Recruiting nowThis early-phase trial tests whether adding two inhaled antibiotics (aztreonam and vancomycin) to the standard cancer drug pembrolizumab can help treat advanced non-small cell lung cancer (NSCLC). The idea is that harmful bacteria in the lungs may help tumors grow, so clearing th…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New hope for rare cancer: oral pill targets early mesothelioma in High-Risk patients
Disease control Recruiting nowThis study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma that is not yet causing symptoms. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will receive tre…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Could immunotherapy spare throat cancer patients from losing their voice?
Disease control Recruiting nowThis phase 2 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy can help people with advanced laryngeal or hypopharyngeal cancer avoid having their voice box removed. The study will enroll 87 adults whose cancer has not been treated before…
Phase 2 • Sponsor: Matthew Spector • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Lung cancer vaccine trial aims to stop tumors from coming back
Disease control Recruiting nowThis study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Diabetes drug tested as new asthma treatment for overweight patients
Disease control Recruiting nowThis study tests whether metformin, a common diabetes medication, can improve asthma control in overweight or obese adults whose asthma is not well-managed by their current inhalers. About 100 participants will take either metformin or a placebo for 24 weeks while tracking their …
Phase 2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Engineered immune cells take on metastatic tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New drug AVZO-1418 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.
Phase 1/2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
Could less be more? new study tests lower doses of cancer drug
Disease control Recruiting nowThis study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with missing gene
Disease control Recruiting nowThis study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …
Phase 1/2 • Sponsor: Tango Therapeutics, Inc. • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New drug cocktail targets tough lung cancer
Disease control Recruiting nowThis study tests a new drug called ZL-1310, alone or with standard treatments (atezolizumab and carboplatin), in people with small cell lung cancer. About 339 participants will join to see if the combination is safe and shrinks tumors. The goal is to find better ways to control t…
Phase 1 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Oct 18, 2026 00:00 UTC
-
New drug cocktail aims to extend life in tough lung cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New combo aims to stop lung cancer return after surgery
Disease control Recruiting nowThis study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New combo therapy aims to extend life in advanced lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New asthma combo pill for kids shows promise in Late-Stage trial
Disease control Recruiting nowThis study tests a new once-daily inhaler called QMF149 (a combination of indacaterol and mometasone) against a standard asthma drug, budesonide, in 200 children aged 6 to 12 with asthma. The goal is to see if the new drug works better at improving lung function and controlling a…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New peptide drug targets lung scarring in IPF
Disease control Recruiting nowResearchers are testing an experimental drug called ORJ-001 in adults with idiopathic pulmonary fibrosis, a condition that scars the lungs and makes breathing hard. The trial has two parts: first, they check whether the drug is safe and well tolerated; second, they measure whethe…
Phase 2 • Sponsor: Oorja Bio, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New triple inhaler could simplify asthma care for teens
Disease control Recruiting nowThis study tests a new once-daily inhaler called QVM149, which combines three medicines (indacaterol, glycopyrronium, and mometasone furoate) to control asthma. It will enroll 304 teenagers aged 12 to 17 and compare the new inhaler to a standard twice-daily treatment (salmeterol/…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New pill aims to keep HER2 lung cancer from returning after surgery
Disease control Recruiting nowThis study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New pill targets Hard-to-Treat KRAS cancers in first human trial
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body proce…
Phase 1 • Sponsor: Kestrel Therapeutics, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Ultrasound-Guided ventilation aims to cut ARDS deaths
Disease control Recruiting nowThis study tests whether using lung ultrasound to personalize ventilator settings can reduce deaths in people with acute respiratory distress syndrome (ARDS). About 538 adults on breathing machines will be assigned to either standard care or a personalized plan based on their lun…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Antibody-drug conjugate targets relapsed small cell lung cancer
Disease control Recruiting nowResearchers are testing becotatug vedotin, an antibody-drug conjugate, in adults with small cell lung cancer that has progressed or returned after earlier treatment. Participants receive the drug by intravenous infusion every three weeks until the cancer worsens or side effects b…
Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug enters human testing
Disease control Recruiting nowThis early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Could TB treatment be cut from 6 months to 8 weeks? major trial launches
Disease control Recruiting nowThis study tests new drug combinations to treat pulmonary tuberculosis (TB) faster than the standard 24-week regimen. About 2500 adults with TB will receive one of several experimental combinations, including two new drugs (BTZ-043 and GSK3036656), for 8 to 16 weeks. Researchers …
Phase 2 • Sponsor: University College, London • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New liposomal drug takes on advanced cancers
Disease control Recruiting nowThis study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…
Phase 1/2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New hope for lung cancer: LIBRA trial tests smart drug cocktails
Disease control Recruiting nowThis study tests several new drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors. About 278 adults will take part across 10 countries. The study is open to those with a speci…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New hope for small cell lung cancer: immunotherapy after surgery
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. About 65 adults who had their cancer completely removed will receive the combination for 12 weeks, then durva…
Phase 2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Inhaled sirolimus trial aims to ease breathing in lung scar patients
Disease control Recruiting nowThis Phase 2 trial tests an inhaled drug called LAM-001 (sirolimus) in 85 adults who have pulmonary hypertension (high blood pressure in the lungs) along with interstitial lung disease (lung scarring). The study compares the drug to a placebo to see if it improves blood flow in t…
Phase 2 • Sponsor: IRulya Therapeutics Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New pill targets HER2 lung cancer in major trial
Disease control Recruiting nowThis Phase 3 trial is testing a new oral drug, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 participants will be randomly assigned to receive either sevabertinib twice daily…
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New inhaled therapy aims to slow lung scarring in IPF
Disease control Recruiting nowThis study tests an inhaled version of the drug nintedanib (called AP02) in people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 160 adults aged 40 and older who are not currently on IPF treatment will take either a low o…
Phase 2 • Sponsor: Avalyn Pharma Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug MDX2001 tested in 285 patients with advanced cancers
Disease control Recruiting nowThis study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…
Phase 1/2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Can an old immune drug make lung cancer treatment hit harder?
Disease control Recruiting nowResearchers are testing whether adding cyclosporine to the standard EGFR-targeted drug osimertinib helps clear tumor DNA from the blood in people with metastatic EGFR-mutant non-small cell lung cancer. All participants start osimertinib for three weeks, then those who still have …
Phase 2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New pill aims to keep High-Risk COVID patients out of the hospital
Disease control Recruiting nowThis study tests an oral medication called ibuzatrelvir in adults and teens with COVID-19 who are not hospitalized but have a high risk of becoming severely ill. Participants will receive either the drug or a placebo for 5 days, and researchers will track whether it reduces emerg…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New hope for Hard-to-Treat lung cancer? osimertinib trial launches
Disease control Recruiting nowThis phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Experimental combo targets tough lung cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs, lurbinectedin and osimertinib, is safe and effective for a rare type of lung cancer called transformed small cell lung cancer. The study will enroll 16 adults whose cancer has changed from a common form to this more a…
Phase 1/2 • Sponsor: Misty Shields • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New registry tracks Dupilumab's Real-World impact on COPD
Disease control Recruiting nowThis registry will follow 350 COPD patients starting dupilumab (Dupixent) to see how well it works and how safe it is in real life. Researchers will track flare-ups, lung function, and quality of life over 24 months, comparing them to similar patients not on the drug. The goal is…
Sponsor: Sanofi • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
Double immunotherapy may keep nasopharyngeal cancer at bay
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy drug relatlimab to standard nivolumab maintenance therapy can extend the time before cancer grows or spreads in patients with recurrent or metastatic nasopharyngeal cancer linked to Epstein-Barr virus. Participants first …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug combo aims to outperform standard care in aggressive lung cancer
Disease control Recruiting nowThis Phase 3 trial will test whether a new drug called BL-M14D1 combined with atezolizumab works better than the current standard treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. About 550 adults will be randomly assigned to receive…
Phase 3 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New combo therapy aims to control lung cancer in First-Line patients
Disease control Recruiting nowThis study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…
Phase 2/3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New drug XB010 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…
Phase 1 • Sponsor: Exelixis • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…
Phase 1/2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Oct 17, 2026 00:00 UTC
-
New antibody EPI-326 enters first human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…
Phase 1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New cell therapy targets common cancer mutation in early trial
Disease control Recruiting nowThis early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Can focused radiation boost Immunotherapy's power against advanced cancer?
Disease control Recruiting nowThis phase II trial is testing whether adding a type of precise radiation called stereotactic body radiation therapy (SBRT) to standard immunotherapy can help people with stage IV cancers, including head and neck, lung, cervical, esophageal, and gastric cancers. Participants will…
Phase 2 • Sponsor: Mark Bernard • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New inhaled drug could help lung disease patients breathe easier and walk farther
Disease control Recruiting nowThis study tests an inhaled medicine called L606 for people with high blood pressure in the lungs due to lung disease. About 344 adults will be randomly assigned to receive L606 or a placebo. The main goal is to see if L606 helps them walk farther in six minutes and delays worsen…
Phase 3 • Sponsor: Liquidia Technologies, Inc. • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New combo aims to shrink tumors and cut radiation for young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New pill aims to halt lung scarring in thousands
Disease control Recruiting nowThis study tests a drug called nerandomilast in 466 adults with fibrosing interstitial lung disease (ILD) who are at risk of worsening. Participants take either the drug or a placebo for at least 52 weeks. Doctors measure lung function and use CT scans to see if the drug slows di…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New hope for aggressive lung cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug (atezolizumab) plus the same chemo. About 621 adults who have not yet been treated for their can…
Phase 3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New drug YL202 targets tough cancers in latest trial
Disease control Recruiting nowThis phase 2 trial tests a new drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers. The drug is given through an IV and aims to shrink tumors or stop them from growing. Researchers will check how well it works and mon…
Phase 2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Biomarker-Guided combo aims to outsmart tough cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New hope for rare lung cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…
Phase 3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Cooling time trial for kids after heart stopping: could longer be better?
Disease control Recruiting nowThis study tests different lengths of body cooling in children who remain unconscious after a cardiac arrest outside the hospital. The goal is to see if longer cooling helps protect the brain and improve recovery. The trial will enroll 900 children and follow them for one year.
Sponsor: University of Michigan • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Cancer patients on targeted therapy get extended safety monitoring
Disease control Recruiting nowThis study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Could immunotherapy replace Chemo-Radiation after head and neck cancer surgery?
Disease control Recruiting nowThis phase II trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) alone can work better than the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 w…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Can a second RSV shot in pregnancy protect more babies?
Disease control Recruiting nowThis study tests whether giving a second dose of an RSV vaccine to pregnant women who already received it in a prior pregnancy is safe and boosts immunity. About 550 women aged 18-49, between 24-36 weeks pregnant, will receive either the vaccine or a placebo. Researchers will tra…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Artificial bronchus implant aims to open blocked airways in severe emphysema
Disease control Recruiting nowThis study tests a new device called an implantable artificial bronchus (IAB) for people with severe emphysema or COPD. The IAB is designed to help air move in and out of the lungs more easily. About 60 adults will receive the implant and be followed for 90 days to see if it impr…
Sponsor: Pulmair Medical, Inc. • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New drug could keep lung cancer from coming back after surgery
Disease control Recruiting nowThis phase 3 trial tests whether the immunotherapy drug cemiplimab can prevent lung cancer from returning after surgery in patients with stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 levels of 1% or higher. About 390 participants will either receive cem…
Phase 3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called KO-2806, alone or with other cancer drugs, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and check for early signs of tumor shrinkage. About 300 participants wi…
Phase 1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Can a new drug shrink nasal polyps and restore smell?
Disease control Recruiting nowThis phase 3 trial tests whether the experimental drug felcorekibart, added to standard care, can reduce nasal polyps and improve symptoms like nasal blockage and loss of smell in adults with chronic rhinosinusitis with nasal polyps. Participants receive either felcorekibart or a…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New pill aims to cut dangerous lung Flare-Ups in bronchiectasis
Disease control Recruiting nowThis study tests a daily pill called BI 1291583 (Verducatib) in 1755 adults and teens with bronchiectasis, a lung condition causing frequent infections and coughing. Participants take either the drug or a placebo for up to 76 weeks. The main goal is to see if the drug reduces the…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New pill combo aims to protect vulnerable from severe COVID
Disease control Recruiting nowThis phase 3 trial tests a new antiviral pill, ibuzatrelvir, alone or with an IV drug (remdesivir) in 300 adults with weak immune systems who have mild-to-moderate COVID-19. The goal is to see if the combination prevents hospitalizations or worsening symptoms better than remdesiv…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New combo therapy aims to stop head and neck cancer from returning
Disease control Recruiting nowThis phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
Can a targeted radiation boost slow advanced lung cancer?
Disease control Recruiting nowThis trial is testing whether giving radiotherapy to the main lung tumour, in addition to standard chemotherapy or immunotherapy, can reduce cancer spread and help people with metastatic non-small-cell lung cancer live longer. Around 420 adults with newly diagnosed stage IV lung …
Phase 3 • Sponsor: Trans Tasman Radiation Oncology Group • Aim: Disease control
Last updated Oct 16, 2026 00:00 UTC
-
New smart drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for rare lung disease: investigational drug now available through expanded access
Disease control Expanded accessThis program offers adults with autoimmune pulmonary alveolar proteinosis (aPAP) access to an investigational inhaled medication called molgramostim. aPAP is a rare lung condition where surfactant builds up, making breathing difficult. The drug aims to help the lungs clear this b…
Sponsor: Savara Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New asthma drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called PF-07275315 for adults with moderate-to-severe asthma that is not well controlled. Participants will receive either the drug or a placebo as injections over 12 weeks. The goal is to see if the drug improves lung function and is safe. About 2…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a Ready-Made mRNA vaccine train the immune system to fight many cancers?
Disease control Recruiting nowThis Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Sound waves may help cancer drugs reach the brain
Disease control Recruiting nowThis study tests whether a focused ultrasound device can safely open the blood-brain barrier in people with non-small cell lung cancer that has spread to the brain. About 30 participants will receive standard immunotherapy plus the ultrasound procedure. The goal is to see if this…
Phase 3 • Sponsor: InSightec • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for advanced cancer patients as experimental drug enters human testing.
Disease control Recruiting nowThis early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
First-in-Human trial tests BA1302 against advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase 1 trial of BA1302, an intravenous drug, in adults with advanced solid tumors including melanoma, breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma. The trial has two parts: a dose-escalation phase to find a saf…
Phase 1 • Sponsor: Shandong Boan Biotechnology Co., Ltd • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a new drug combo slow advanced head and neck cancer?
Disease control Recruiting nowThis phase 2 trial tests an experimental drug called ficerafusp alfa, which targets two proteins that help tumors grow, when given with the immunotherapy pembrolizumab. The study enrolls adults with recurrent or metastatic head and neck squamous cell carcinoma that has not been t…
Phase 2 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New Alpha-Particle therapy targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called [212Pb]VMT-α-NET, which delivers a powerful type of radiation (alpha particles) directly to tumor cells that have a specific marker (SSTR2). The trial includes 300 adults with advanced neuroendocrine tumors or meningioma that cannot be removed b…
Phase 1/2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat lung tumors
Disease control Recruiting nowThis study tests two drugs, sacituzumab govitecan and ivonescimab, alone or together, in people with advanced non-small cell lung cancer that has specific gene changes. The goal is to see if the combination works better than either drug alone at shrinking tumors and delaying canc…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for lung cancer patients: targeted drug Dato-DXd faces off against chemo
Disease control Recruiting nowThis phase 3 trial compares a new targeted drug, datopotamab deruxtecan (Dato-DXd), against the standard chemotherapy docetaxel in 400 people with advanced or metastatic non-squamous non-small cell lung cancer that lacks certain gene mutations. The goal is to see if Dato-DXd can …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New inhaler combo could help kids with asthma breathe easier
Disease control Recruiting nowThis study tests whether adding an extra medication called glycopyrronium to standard asthma treatment can improve lung function in children aged 4 to 12. About 69 children with asthma will receive two different doses of glycopyrronium or a placebo, all on top of their usual inha…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New pill targets tough lung cancers in first human trial
Disease control Recruiting nowThis study tests a new oral drug, BAY 2927088, for people with advanced non-small cell lung cancer that has specific EGFR or HER2 mutations. The trial has four parts to find the safest dose and see if the drug shrinks tumors. About 400 participants will take the drug daily until …
Phase 1/2 • Sponsor: Bayer • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Engineered IL-2 drug tested against resistant cancers
Disease control Recruiting nowResearchers are testing an engineered interleukin-2 drug called MDNA11 in adults with advanced solid tumors. The trial gives MDNA11 alone or with pembrolizumab, an immune checkpoint inhibitor, to see which doses are safe and how the body processes the drug. It also looks for earl…
Phase 1/2 • Sponsor: Medicenna Therapeutics, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug combo aims to fight aggressive lung cancer
Disease control Recruiting nowThis study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New inhaled therapy could help preterm infants breathe easier
Disease control Recruiting nowThis Phase 3 trial tests a new inhaled medication called APC-0101 in 520 premature babies born between 26 and 33 weeks who have respiratory distress syndrome. The drug is a surfactant that helps keep tiny air sacs in the lungs open. Some babies receive the active drug through a s…
Phase 3 • Sponsor: Aerogen Pharma Limited • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for advanced lung cancer: experimental drug takes on chemo in major trial
Disease control Recruiting nowThis study compares an experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive one of the two drugs by …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for lung cancer: personalized drug cocktails before surgery
Disease control Recruiting nowThis study tests different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. The drugs are chosen based on specific genetic markers in each person's tumor. The goal is to see if these treatments shrink the tumor before surge…
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
AI-Designed drug targets scarred lungs in major trial
Disease control Recruiting nowThis phase 3 trial tests whether the oral drug rentosertib (INS018_055) can slow lung function decline in adults with idiopathic pulmonary fibrosis (IPF), a progressive lung disease. About 320 participants will receive either rentosertib or a placebo daily for 52 weeks. The main …
Phase 3 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for aggressive lung cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Two immune drugs join forces against aggressive lung cancer
Disease control Recruiting nowResearchers are testing two experimental immune-stimulating drugs, obrixtamig and pumitamig, in adults with extensive-stage small cell lung cancer. One group receives the two drugs alone; another receives them with standard chemotherapy (carboplatin and etoposide). All treatments…
Phase 1/2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug BL-M07D1 targets multiple HER2 cancers in early trial
Disease control Recruiting nowThis Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
A pill that could outsmart food allergies? trial tests remibrutinib
Disease control Recruiting nowThis Phase 3 study is testing whether an oral drug called remibrutinib can help people with IgE-mediated allergies to peanuts, cow's milk, or hen's egg tolerate larger amounts of the allergen without symptoms. Adults and adolescents aged 12 to 65 will receive either the drug or a…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Inhaled powder tested as potential asthma therapy
Disease control Recruiting nowResearchers are testing an experimental drug called CHF10136 to see if it is safe and well tolerated when inhaled as a dry powder. The trial includes healthy adults and adults with mild to moderate-to-severe asthma. Participants receive single or multiple doses through a dry powd…
Phase 1 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for lung cancer patients with rare gene mutations
Disease control Recruiting nowThis study tests the drug cabozantinib in people with advanced non-small cell lung cancer whose tumors have certain gene changes (RET, ROS1, NTRK fusions or increased MET/AXL activity). The drug is taken by mouth and aims to shrink tumors and stop them from growing. About 86 part…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New pill plus chemo aims to stop lung cancer comeback in patients with rare mutations
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug zipalertinib to standard chemotherapy can delay or prevent lung cancer from returning in people with early-stage non-small cell lung cancer (stages IB to IIIA) who have uncommon EGFR mutations. After complete tumor removal…
Phase 3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New targeted pill aims to keep KRAS lung cancer from returning after surgery
Disease control Recruiting nowThis study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Could amniotic fluid mist help heal scarred lungs?
Disease control Recruiting nowThis early-stage study tests whether inhaling a mist made from donated human amniotic fluid is safe for people with interstitial lung disease (ILD), a condition that scars the lungs and makes breathing hard. About 50 adults aged 40 to 90 with mild to moderate ILD will receive the…
Phase 1 • Sponsor: Maule Stem Cell Research Institute, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Could a spinal implant tame Hard-to-Control asthma?
Disease control Recruiting nowThis study tests whether a device that stimulates the spinal cord — called pulmonary neuromodulation — can improve asthma control in adults with moderate to severe asthma that remains uncontrolled despite high-dose inhalers or biologic medications. Participants receive the implan…
Sponsor: Spiro Medical, Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for KRAS lung cancer: targeted combo enters phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug adagrasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 630 adults who have not had …
Phase 3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for tough lung cancer: targeted drug combo takes on standard care
Disease control Recruiting nowThis study tests whether a new drug combo (sotorasib plus chemotherapy) works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has a specific KRAS G12C gene change and low PD-L1 levels. About 750 adults wh…
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers? first human trial launches
Disease control Recruiting nowThis early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…
Phase 1 • Sponsor: Axcynsis Therapeutics Pte Ltd • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Recruiting nowThis early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New inhaler combo aims to cut severe asthma Flare-Ups in teens
Disease control Recruiting nowThis study tests a new inhaler (PT027) against a standard one (PT007) in 440 teens aged 12 to 18 with asthma. The goal is to see if PT027 reduces the number of severe asthma attacks over a year. Participants must have had at least one severe attack in the past year and use daily …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New asthma drug could help kids breathe easier
Disease control Recruiting nowThis study tests whether tezepelumab, an injectable drug, can reduce severe asthma attacks in children aged 5 to 11 with hard-to-control asthma. About 231 kids will receive either tezepelumab or a placebo, alongside their usual asthma medicines. The main goal is to see if the dru…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Hope for kids with scarred lungs: new drug trial launches
Disease control Recruiting nowThis study tests a medicine called nerandomilast in children aged 2 to 17 with fibrosing interstitial lung disease, a condition where lung tissue becomes scarred and stiff. The goal is to see if the drug is safe and how the body processes it, and to get early signs of whether it …
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New combo therapy aims to halt ALK-Positive lung cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding local treatments (like radiation or surgery) to the drug lorlatinib can better control advanced ALK-positive non-small cell lung cancer. About 30 patients who have not had prior targeted therapy will receive lorlatinib for 12 weeks, then ma…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…
Phase 1/2 • Sponsor: Accent Therapeutics • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for hard-to-treat lung cancer: targeted drug plus immunotherapy tested
Disease control Recruiting nowThis study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…
Phase 2/3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug targets KRAS mutations in advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…
Phase 1 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New hope for advanced cancers? pfizer launches early trial of PF-08046033
Disease control Recruiting nowThis early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Disease control Recruiting nowThis study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…
Phase 4 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New drug cocktail aims to shrink lung tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery to people with stage III non-small cell lung cancer. The goal is to see if this approach can eliminate or greatly reduce the tumor before it is removed. The st…
Phase 2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Experimental combo aims to reignite immune attack on lung cancer
Disease control Recruiting nowThis phase 2 trial tests whether combining SX-682 (a drug that blocks certain immune-suppressing proteins) with atezolizumab (an immunotherapy) can shrink tumors in people with advanced non-small cell lung cancer that has worsened after chemotherapy and immunotherapy. About 32 ad…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New asthma drug candidate enters first human safety tests
Disease control Recruiting nowThis early-stage study tests a new experimental drug, PF-08103402, for the first time in people. It includes healthy adults and adults with mild-to-moderate asthma to check safety, how the drug moves through the body, and whether food affects its absorption. Participants take the…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
New inhaled drug aims to help lung patients breathe and move easier
Disease control Recruiting nowThis phase 3 trial tests an inhaled drug called treprostinil palmitil in 344 adults with pulmonary hypertension caused by interstitial lung disease. Participants take the drug or a placebo once daily for 24 weeks. The main goal is to see if the drug helps them walk farther in six…
Phase 3 • Sponsor: Insmed Incorporated • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Could a pill replace the CPAP machine for sleep apnea?
Disease control Recruiting nowThis Phase 2 trial tests IHL-42X, a combination of two drugs (dronabinol and acetazolamide), in people with obstructive sleep apnea. The study aims to see if the drug can reduce the number of breathing pauses during sleep and improve daytime symptoms. Participants will receive di…
Phase 2 • Sponsor: Incannex Healthcare Ltd • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Oct 15, 2026 00:00 UTC
-
Less radiation, same control? new trial aims to boost quality of life for throat cancer patients
Disease control Recruiting nowThis study tests whether a shorter, lower-dose course of radiation after robotic surgery can improve quality of life for people with HPV-related throat cancer. About 42 adults who have had robotic surgery will receive a reduced radiation schedule. The goal is to see if this appro…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Could a Triple-Drug combo shrink lung tumors better?
Disease control Recruiting nowThis study is for people with stage IV or returning non-small cell lung cancer who have already had chemotherapy and immunotherapy. It compares the usual two-drug treatment (docetaxel and ramucirumab) to the same two drugs plus a third drug called cemiplimab. The goal is to see i…
Phase 2/3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Can a targeted pill offer hope for Hard-to-Treat lung cancer?
Disease control Expanded accessThis program provides early access to divarasib, an experimental oral drug designed to target the KRAS G12C mutation found in some non-small cell lung cancers. It is open to adults with advanced or metastatic disease that has progressed after at least one prior standard treatment…
Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New shot could tame COPD Flare-Ups in severe patients
Disease control Recruiting nowThis Phase 3 trial tests whether tezepelumab, a biologic drug given as a shot, can reduce the number of moderate to severe COPD flare-ups in adults aged 40 to 80. About 990 participants with moderate to very severe COPD will receive either tezepelumab or a placebo for up to 76 we…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New combo targets Hard-to-Treat lung cancer mutation
Disease control Recruiting nowThis study tests whether adding ramucirumab to tepotinib works better than tepotinib alone for people with advanced non-small cell lung cancer that has a specific MET gene mutation. About 56 participants will be randomly assigned to one of two treatment groups. The goal is to see…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Blood marker may help doctors spot and treat respiratory failure before it worsens
Disease control Recruiting nowThis study tests whether measuring a blood marker called interleukin-6 (IL-6) can help doctors decide when to give anti-inflammatory drugs to patients hospitalized with acute respiratory failure. Patients with high IL-6 levels will receive either standard care, a single dose of t…
Phase 2 • Sponsor: Lorenzo delSorbo • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Can a new biologic drug prevent COPD Flare-Ups?
Disease control Recruiting nowThis phase 2 trial tests whether galvokimig, an experimental biologic drug, can reduce the number of moderate-to-severe COPD flare-ups in people with chronic bronchitis. About 400 adults aged 40 to 80 with moderate-to-severe COPD will receive either galvokimig or a placebo as an …
Phase 2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Can a monthly shot cut severe asthma attacks?
Disease control Recruiting nowResearchers are testing an experimental medicine called tilrekimig in adults and teens with severe asthma. Participants receive either tilrekimig or a placebo as a shot about every four weeks for a year. The trial measures how many asthma attacks each group has, to see whether ti…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New ventilator method may save fragile preemies from breathing tubes
Disease control Recruiting nowThis study compares two ways to help extremely premature babies (born at 25-28 weeks) breathe right after birth. One method uses a standard manual T-piece device; the other uses a ventilator to deliver gentle puffs of air through a nasal mask. The goal is to see if the ventilator…
Sponsor: Michelle Baczynski • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Cancer drug adagrasib offers continued hope in rollover trial
Disease control Recruiting nowThis study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…
Phase 2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Can a new drug shrink nasal polyps and restore smell?
Disease control Recruiting nowThis phase 3 trial tests whether an experimental drug called felcorekibart can reduce nasal polyps and improve symptoms like nasal blockage and loss of smell in adults with chronic rhinosinusitis with nasal polyps. Participants receive either felcorekibart or a placebo on top of …
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Targeted drug aims to shrink MET-positive lung tumors
Disease control Recruiting nowThis study tests a drug called amivantamab, given as a shot under the skin, for people with advanced non-small cell lung cancer that has extra copies of the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing. About 88 participants will take part …
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New blood test aims to slash unnecessary antibiotics in ER lung infections
Disease control Recruiting nowThis study tests a new blood test called MeMed BV in about 1,300 adults with suspected lower respiratory infections (like bronchitis or pneumonia) in the ER. The goal is to see if the test helps doctors prescribe antibiotics only when truly needed, reducing unnecessary use. Parti…
Sponsor: MeMed Diagnostics Ltd. • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New hope for rare lung cancer: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops from another lung cancer type. About 40 participants will receive the drug combo through IV infusions…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New drug combo aims to fight tough lung cancer
Disease control Recruiting nowThis study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy and immunotherapy, for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 170 participants…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New hope for EGFR lung cancer patients after targeted therapy fails
Disease control Recruiting nowThis study tests a new drug called izalontamab brengitecan against standard chemotherapy in 500 people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that has stopped responding to current targeted pills. The goal is to see if the new drug can delay…
Phase 2/3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
New hope for KRAS lung cancer: targeted pill plus immunotherapy in Late-Stage trial
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Radioactive drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Oct 11, 2026 00:00 UTC
-
Virus cocktail targets tough lung bugs in cystic fibrosis trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called AchromoPhage, a mix of four viruses that specifically kill Achromobacter bacteria, in 12 adults with cystic fibrosis and chronic lung infections. Participants will receive the treatment by inhalation, IV, or both over three week…
Phase 1 • Sponsor: Ghady Haidar • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Pfizer launches early trial of PF-08634404 combo for tough lung cancers
Disease control Recruiting nowThis study tests a new experimental drug called PF-08634404 combined with other cancer medicines in people with advanced non-small cell lung cancer that has spread and can't be surgically removed. The trial has two parts: one combining PF-08634404 with sigvotatug vedotin, and ano…
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can a new injection ease COPD and cut Flare-Ups?
Disease control Recruiting nowThis trial is testing an investigational drug called brenipatide in adults with moderate-to-severe COPD. Participants will receive either brenipatide or a placebo for about a year, alongside standard care. The goal is to see if brenipatide improves lung function and reduces the n…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New drug duo aims to outsmart EGFR-mutant lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding an experimental drug called izalontamab brengitecan to the standard targeted therapy osimertinib works better than osimertinib alone or with chemotherapy for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New drug targets Hard-to-Treat lung cancer mutation in major trial
Disease control Recruiting nowThis study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer…
Phase 3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New pill hopes to ease breathing in rare lung conditions
Disease control Recruiting nowThis study tests an experimental oral drug called ROC-101 in 40 adults with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (ILD-PH). Participants take the drug alongside their standard care for 24 weeks, with a long-term follow…
Phase 2 • Sponsor: AllRock Bio, Inc. • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can a Lab-Made antibody disarm a stubborn lung infection?
Disease control Recruiting nowThis trial tests an experimental drug called AZD0292 in adults with bronchiectasis who have a chronic Pseudomonas aeruginosa infection in their lungs. The goal is to see if the drug, given by IV infusion, can reduce the number of moderate-to-severe lung flare-ups (exacerbations) …
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New immune drug AZD6750 targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New lung cancer drug shows promise in early trial
Disease control Recruiting nowThis study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Smarter radiation: could less be more for throat cancer patients?
Disease control Recruiting nowThis study tests whether giving less radiation to healthy lymph nodes can reduce side effects for people with oropharynx cancer. The approach uses a computer model to personalize which lymph nodes need treatment. The trial will enroll 120 patients and track if cancer returns in u…
Phase 2 • Sponsor: University of Zurich • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Botox injections studied for movement disorder relief
Disease control Recruiting nowThis study uses botulinum toxin (Botox) injections to treat movement disorders such as dystonia, tremor, and spasticity. Up to 2,000 participants aged 2 and older will receive tailored injections, with doctors trained in proper techniques. The goal is to manage symptoms and build…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New lung cancer combo aims to beat current standard
Disease control Recruiting nowThis study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can focused radiation save memory while fighting brain tumors?
Disease control Recruiting nowResearchers are comparing two ways to treat small-cell lung cancer that has spread to the brain. One approach uses focused, high-dose radiation on each tumor. The other uses whole brain radiation that avoids the hippocampus, the brain's memory center. The trial measures memory an…
Phase 3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New drug combo takes on tough lung cancer
Disease control Recruiting nowThis study tests a new medicine called PF-08634404 given with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The trial has two parts: first checking safety, then comparing the new combo to an approved treatment (atezoli…
Phase 2/3 • Sponsor: Pfizer • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New trial aims to find best treatment for older lung cancer patients
Disease control Recruiting nowThis phase III trial compares adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in adults aged 70+ with advanced non-small cell lung cancer. The goal is to see if the combination improves survival. About 304 participants will be enrolled.
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can a tree bark extract help fight lung cancer? new trial begins
Disease control Recruiting nowThis early-stage trial tests the safety of honokiol, a dietary supplement from magnolia bark, in 15 people with early lung cancer. Participants take honokiol for two weeks before their scheduled surgery. The goal is to find the highest safe dose and check for side effects.
Phase 1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can severe asthma patients safely quit their biologic?
Disease control Recruiting nowResearchers are testing whether adults with well-controlled severe asthma can stop taking dupilumab after at least three years, or whether continuing the drug is better. The trial compares two groups: one stops dupilumab, the other keeps taking it. Over 24 months, researchers tra…
Phase 4 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New weekly shot aims to treat sleep apnea and obesity together
Disease control Recruiting nowThis phase 3 trial tests a weekly injection called eloralintide in 800 adults with moderate-to-severe obstructive sleep apnea who are also overweight or have obesity. The study looks at whether the drug can improve sleep apnea symptoms and help with weight loss. Participants are …
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New pill could tame lung inflammation in sarcoidosis
Disease control Recruiting nowThis Phase 2 trial tests OATD-01, an oral drug that blocks a protein called chitinase-1, in 96 people with active pulmonary sarcoidosis. Participants take the drug or a placebo for 12 weeks to see if it reduces lung inflammation measured by PET scans. The goal is to find a new tr…
Phase 2 • Sponsor: Molecure S.A. • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New asthma drug brenipatide enters Mid-Stage trial
Disease control Recruiting nowThis study tests whether the experimental drug brenipatide can reduce asthma attacks and improve breathing in adults whose moderate-to-severe asthma is not well controlled by current treatments. About 531 participants will receive either brenipatide or a placebo for 52 weeks. The…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New hope for tough lung cancer: drug combo targets liver spread
Disease control Recruiting nowThis study tests whether adding the drug bevacizumab to standard chemo-immunotherapy can help people with extensive-stage small cell lung cancer that has spread to the liver. About 39 participants will receive the combination for up to a year. The goal is to see if it delays canc…
Phase 2 • Sponsor: Kamya Sankar • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Can a smart chemo drug outsmart advanced throat cancer?
Disease control Recruiting nowThis trial is testing whether CRB-701, a targeted chemotherapy that delivers a potent drug directly to cancer cells, can shrink tumors and extend life in people with recurrent or metastatic oropharyngeal (throat or tonsil) cancer. Participants will have already tried platinum-bas…
Phase 3 • Sponsor: Corbus Pharmaceuticals Inc. • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
Chest vibrations may boost lung sample collection
Disease control Recruiting nowThis trial tests whether a device that sends gentle vibrations through the chest can help people with COPD cough up more sputum (mucus) during a standard collection procedure. Each participant undergoes the procedure twice—once with the device and once without—to compare the amou…
Sponsor: Fraunhofer-Institute of Toxicology and Experimental Medicine • Aim: Disease control
Last updated Oct 10, 2026 00:00 UTC
-
New drug combo aims to tackle tough lung cancer mutation
Disease control Recruiting nowThis Phase 3 study tests whether adding olomorasib (a targeted pill) to standard immunotherapy (pembrolizumab or durvalumab) works better than immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer. The trial has two parts: one for patients whose cancer w…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New CAR t cell therapy targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis early-phase trial tests a new type of immunotherapy for people with a specific kind of advanced lung cancer (FRa-positive NSCLC). Researchers take a patient's own immune cells, engineer them to recognize and attack cancer cells, and deliver them directly into the chest cavit…
Phase 1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New combo aims to stop KRAS-Mutant lung cancer from coming back
Disease control Recruiting nowThis Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
Double-Target antibody joins chemo in lung cancer surgery trial
Disease control Recruiting nowResearchers are testing whether adding a dual-action antibody that targets both PD-L1 and VEGF to chemotherapy before surgery helps people with locally advanced non-small cell lung cancer. The trial enrolls about 290 adults with stage II or III NSCLC who have not yet received ant…
Phase 3 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control Recruiting nowThis early-stage study is testing a new drug called calderasib (MK-1084) in people with advanced solid tumors that have a specific KRAS G12C mutation. The drug is given alone or combined with other cancer treatments. The main goals are to check safety and find the right dose. Abo…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
Tailored radiation blasts lung tumors faster in new trial
Disease control Recruiting nowThis phase 1 trial tests a personalized, accelerated radiation therapy for locally advanced lung cancer. The radiation dose is tailored to each patient's tumor size and location, aiming to deliver a higher dose in fewer sessions. The study will enroll 45 adults with non-small cel…
Sponsor: Stanford University • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
Can a tailored approach help smokers quit for good?
Disease control Recruiting nowThis study tests whether matching smoking cessation treatments—like nicotine patches, counseling, or medications—to a person's unique traits can help them quit. About 2,010 smokers who want to quit will receive personalized care. The goal is to find better ways to help people sto…
Phase 4 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
Smart bombs for lung cancer: new ADC drugs enter trial
Disease control Recruiting nowThis phase 2 trial tests two antibody-drug conjugates (ADCs) — R-DXD and I-DXD — against standard chemotherapy in 144 people with advanced squamous non-small cell lung cancer that has worsened after initial treatment. ADCs are like guided missiles that deliver a cancer-killing dr…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
Can a MYC-targeting drug crack platinum-resistant lung cancer?
Disease control Recruiting nowResearchers are testing an experimental drug called IDP-121 alongside standard chemotherapy in adults with small cell lung cancer that has worsened after platinum-based treatment. The trial enrolls about 60 people and gives IDP-121 at increasing doses with either topotecan or car…
Phase 1/2 • Sponsor: IDP Discovery Pharma S.L. • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New pill plus immunotherapy shows promise for tough lung cancer
Disease control Recruiting nowThis phase 3 study is testing whether adding an experimental pill called calderasib (MK-1084) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and high PD-L1 …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New shot every 6 months could slash severe asthma attacks
Disease control Recruiting nowThis study tests a new medicine called GB-0895 for people aged 12 to 80 with severe asthma that is not controlled by standard inhalers. Participants receive either GB-0895 or a placebo as a shot every 6 months for a year. The goal is to see if GB-0895 can reduce the number of ser…
Phase 3 • Sponsor: Generate Biomedicines • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New asthma drug could cut attacks with just two shots a year
Disease control Recruiting nowThis phase 3 trial tests whether GB-0895, given every 6 months, can reduce asthma attacks in adults and teens (ages 12–80) with severe asthma that isn't controlled by standard inhalers. About 786 participants will receive either GB-0895 or a placebo, and researchers will track ho…
Phase 3 • Sponsor: Generate Biomedicines • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
Oral asthma drug KT-621 tested for Long-Term safety
Disease control Recruiting nowThis study looks at the long-term safety and effectiveness of an oral drug called KT-621 in people with asthma. Participants have already completed a previous KT-621 asthma study. The goal is to see how well the drug works over time and if any side effects appear with longer use.
Phase 2 • Sponsor: Kymera Therapeutics, Inc. • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New drug Rina-S shows promise in battling Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New hope for brain metastases? drug combo trial opens
Disease control Recruiting nowThis study tests whether two drugs, pembrolizumab and lenvatinib, can shrink brain tumors in people with breast cancer, lung cancer, or other solid tumors that have spread to the brain. About 87 participants will receive the combination therapy. The goal is to see how well the tr…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New targeted combo aims to outsmart KRAS lung cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New weekly shot could help sleep apnea and weight loss
Disease control Recruiting nowThis study tests a once-weekly injection called NNC0487-0111 in 300 adults with overweight or obesity and moderate-to-severe obstructive sleep apnea who use a breathing device. The goal is to see if the drug helps with weight loss and reduces breathing pauses during sleep. Partic…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…
Phase 1/2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
New hope for KRAS lung cancer: major trial launches for targeted combo therapy
Disease control Recruiting nowThis global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Oct 09, 2026 00:00 UTC
-
Can the right oxygen dose save tiny lungs? new trial hopes to find out
Disease control Recruiting nowThis study tests whether different oxygen targets (higher vs. lower) improve outcomes in 39 preterm infants with bronchopulmonary dysplasia and pulmonary hypertension. Each infant will experience both oxygen levels in a crossover design. The goal is to see which level reduces dan…
Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Oct 08, 2026 00:00 UTC
-
Spinal fluid vs. blood: can liquid biopsies match up for Hard-to-Treat lung cancer spread?
Diagnosis Recruiting nowResearchers are studying whether tumor DNA found in spinal fluid matches tumor DNA found in blood in people whose EGFR-mutant lung cancer has spread to the leptomeninges, the membranes around the brain and spinal cord. Participants give samples of spinal fluid through a lumbar pu…
Sponsor: British Columbia Cancer Agency • Aim: Diagnosis
Last updated Oct 20, 2026 06:00 UTC
-
Glowing cancer cells: a new way to see tumors during surgery?
Diagnosis Recruiting nowThis trial tests whether two imaging agents, Panitumumab-IRDye800 and [18F]NOTA-ABY-030, are safe and useful for helping surgeons identify head and neck tumors and cancer-containing lymph nodes during surgery. Adults with head and neck squamous cell carcinoma who are scheduled fo…
Phase 1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated Oct 20, 2026 06:00 UTC
-
Home detectives hunt hidden lung triggers
Diagnosis Recruiting nowFibrosing hypersensitivity pneumonitis is a lung-scarring disease caused by breathing in antigens, often from mold, bird proteins, or chemicals at home or work. Doctors cannot identify the trigger in about half of cases, and that gap raises the risk of death. This study at two Fr…
Sponsor: Nantes University Hospital • Aim: Diagnosis
Last updated Oct 18, 2026 00:00 UTC
-
PET scan lights up lung scarring to guide treatment
Diagnosis Recruiting nowResearchers are testing a PET/CT scan that uses a tracer called FAPI to measure fibrotic activity in the lungs of adults with pulmonary fibrosis. The study checks whether lung FAPI uptake drops after patients start anti-fibrotic treatment, and whether those changes match clinical…
Phase 2 • Sponsor: Erasme University Hospital • Aim: Diagnosis
Last updated Oct 18, 2026 00:00 UTC
-
Simple spit test could spot lung cancer early
Diagnosis Recruiting nowThis study is testing a new test called FlowPath Lung that looks for signs of lung cancer in sputum (phlegm). It involves over 2,000 high-risk individuals aged 50-80 who have lung nodules found on CT scans. The goal is to see if this non-invasive test can accurately detect early-…
Sponsor: bioAffinity Technologies Inc. • Aim: Diagnosis
Last updated Oct 18, 2026 00:00 UTC
-
New MRI technique aims to capture the lungs in sharper detail
Diagnosis Recruiting nowResearchers are testing specialized MRI sequences called ultra-short echo time (UTE) and balanced steady-state free precession (bSSFP) to take clearer pictures of the lungs. Standard MRI struggles to image air-filled lung tissue, so these sequences are designed to capture lung st…
Sponsor: Laura Walkup • Aim: Diagnosis
Last updated Oct 18, 2026 00:00 UTC
-
Blood test aims to spare kids unneeded antibiotics
Diagnosis Recruiting nowMany children hospitalized with community-acquired pneumonia receive antibiotics even when a virus is the cause, and those antibiotics do not help viral cases. Researchers are testing whether a blood test called MeMed BV, which measures immune markers, can help doctors identify c…
Sponsor: Jeffrey Pernica • Aim: Diagnosis
Last updated Oct 18, 2026 00:00 UTC
-
Can a new PET tracer light up hidden cancers?
Diagnosis Recruiting nowThis trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…
Sponsor: Peking University Third Hospital • Aim: Diagnosis
Last updated Oct 17, 2026 00:00 UTC
-
Simple 75-Second breath test could revolutionize asthma and COPD diagnosis
Diagnosis Recruiting nowThis study is testing a new, easy way to diagnose asthma and COPD using a handheld device that measures carbon dioxide in a person's breath. Instead of the current uncomfortable and time-consuming lung tests, participants simply breathe normally into the device for 75 seconds. Th…
Sponsor: Liverpool Heart and Chest Hospital NHS Foundation Trust • Aim: Diagnosis
Last updated Oct 17, 2026 00:00 UTC
-
Blood test aims to uncover hidden genetic disorder in lung disease patients
Diagnosis Recruiting nowResearchers are testing a blood-based screening approach to detect acid sphingomyelinase deficiency (ASMD), a rare genetic condition, in people who have interstitial lung disease (ILD) and other risk signs such as an enlarged spleen, low platelet count, or low HDL cholesterol. Th…
Sponsor: Wladimir MAUHIN, Dr • Aim: Diagnosis
Last updated Oct 17, 2026 00:00 UTC
-
Leftover fluid from lung biopsies could reveal Cancer's hidden spread
Diagnosis Recruiting nowDoctors use a procedure called EBUS-TBNA to sample lymph nodes in the chest when they suspect lung cancer has spread. Sometimes the sample misses the cancer, and patients need more invasive surgery to check those nodes. This study asks whether the fluid left over from that same p…
Sponsor: Barzilai Medical Center • Aim: Diagnosis
Last updated Oct 17, 2026 00:00 UTC
-
Blood test could sharpen lung cancer screening, study says
Diagnosis Recruiting nowThis study is testing a blood test that looks for tumor DNA to see if it can more accurately tell whether a lung nodule found on a CT scan is cancer. About 590 people getting lung cancer screening will give blood samples and be followed for 3 years. The goal is to improve how we …
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Oct 16, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers
Diagnosis Recruiting nowThis early-phase study tests a new imaging agent that targets a protein called TROP2, found on many cancer cells. About 40 adults with metastatic bladder, breast, or lung cancer will receive the agent to see where it goes in the body. The goal is to see if this tracer can help do…
Early phase 1 • Sponsor: RayzeBio, Inc. • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
Urine test aims to sniff out lung cancer in Never-Smokers
Diagnosis Recruiting nowResearchers at Thomas Jefferson University are studying whether a urine-based biosensor can detect lung cancer in people who have never smoked. The study includes adults with and without lung cancer who have a suspicious lung nodule found on a CT scan. Participants provide a urin…
Sponsor: Thomas Jefferson University • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
Radioactive tracer homes in on a protein tumors use to survive low oxygen
Diagnosis Recruiting nowResearchers are testing a PET/CT scan that uses a radioactive tracer called 68Ga-CAIX to detect solid tumors. The tracer binds to CAIX, a protein that many solid tumors produce when oxygen is scarce. The study enrolls about 100 adults with suspected or confirmed solid tumors, inc…
Sponsor: Zhongnan Hospital • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
New portable device could speed up asthma diagnosis
Diagnosis Recruiting nowThis study aims to see if a portable device that measures lung function can accurately diagnose asthma in people with symptoms like wheezing or coughing. Researchers will compare this new test to the standard breathing tests currently used. The study plans to enroll 500 adults ac…
Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
Can a new tracer make tumors light up on scans?
Diagnosis Recruiting nowThis trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
Could Ultra-Low-Dose CT reshape emergency pneumonia imaging workload?
Diagnosis Recruiting nowResearchers at the University of Southern Denmark compare how much staff time two chest imaging methods require when adults arrive at the emergency department with suspected community-acquired pneumonia. One method is conventional chest radiography, the other is ultra-low-dose ch…
Sponsor: University of Southern Denmark • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
Could a simple breath test replace specialist diagnosis for lung disease?
Diagnosis Recruiting nowThis study is testing whether two simple breathing tests—oscillometry and FeNO—can help primary care doctors accurately diagnose asthma and COPD, compared to the usual specialist methods. Researchers will enroll 600 adults with suspected asthma or COPD across six countries. If th…
Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
AI could prevent sudden cardiac death in young athletes
Diagnosis Recruiting nowThis study aims to improve how doctors diagnose a rare heart condition where a coronary artery starts in the wrong place (AAOCA), which can cause sudden cardiac death in young athletes. Researchers will use artificial intelligence and 3D computer models to analyze CT scans and pr…
Sponsor: IRCCS Policlinico S. Donato • Aim: Diagnosis
Last updated Oct 15, 2026 00:00 UTC
-
New Full-Body scanner aims to spot hidden cancers
Diagnosis Recruiting nowThis study tests a new total-body PET scanner called the Biograph Vision Quadra to see if it can produce clearer images and find more tumors than standard PET/CT scanners. The study includes adults with non-small cell lung cancer, head and neck cancer, or prostate cancer who are …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Oct 11, 2026 00:00 UTC
-
AI reads your heartbeat to catch silent killer in lung patients
Diagnosis Recruiting nowThis study tests whether an artificial intelligence (AI) tool that analyzes a simple ECG can help doctors find undiagnosed pulmonary hypertension (high blood pressure in the lungs) in people with interstitial lung disease. About 900 adults with severe lung scarring will be random…
Sponsor: Tempus AI • Aim: Diagnosis
Last updated Oct 11, 2026 00:00 UTC
-
Laser and AI team up to spot lung cancer in minutes during surgery
Diagnosis Recruiting nowThis trial investigates whether a femtosecond laser combined with an artificial intelligence model can diagnose lung cancer from fresh tissue samples as accurately as the standard frozen section method. About 294 adults scheduled for lung surgery will have their tumor specimens e…
Sponsor: Shanghai Chest Hospital • Aim: Diagnosis
Last updated Oct 11, 2026 00:00 UTC
-
Blood test aims to detect tumor DNA without biopsy
Diagnosis Recruiting nowResearchers at the Grand Hôpital de Charleroi are validating a molecular test called TST79 that looks for circulating tumor DNA in blood plasma. The study enrolls 15 patients with various cancers, including lung, colorectal, breast, prostate, melanoma, and others, who are undergo…
Sponsor: Grand Hôpital de Charleroi • Aim: Diagnosis
Last updated Oct 11, 2026 00:00 UTC
-
Weight loss could be key to spotting lung cancer sooner
Diagnosis Recruiting nowThis study looks at whether people with unexplained weight loss who are at high risk for lung cancer are more likely to develop the disease. Researchers will use low-dose CT scans and blood tests to screen 409 participants over one year. The goal is to see if adding weight loss t…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Oct 11, 2026 00:00 UTC
-
Blood test may spot lung risk in brain injury patients
Diagnosis Recruiting nowThis study looks at whether a simple blood test, called the fibrinogen-to-albumin ratio, can predict if someone with a traumatic brain injury will develop acute respiratory distress syndrome (ARDS), a serious lung condition. Researchers will measure these proteins in the blood of…
Sponsor: Tanta University • Aim: Diagnosis
Last updated Oct 11, 2026 00:00 UTC
-
AI takes on ear infections: could cut unnecessary antibiotics in kids
Diagnosis Recruiting nowThis study tests whether an AI-powered app can help doctors more accurately diagnose ear infections in young children (6-24 months) with cold symptoms. Researchers will compare standard ear exams with the AI app's analysis of eardrum photos. The goal is to see if the AI reduces u…
Sponsor: Timothy Shope • Aim: Diagnosis
Last updated Oct 10, 2026 00:00 UTC
-
New PET tracer could spot hidden fungal infections
Diagnosis Recruiting nowThis Phase 1 trial tests a new radioactive tracer called [18F]-Fluorocellobiose ([18F]FCB) for PET/CT scans. The goal is to see if it can help find invasive mold infections in the body. The study includes healthy volunteers and people with known fungal infections. Participants re…
Phase 1 • Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Diagnosis
Last updated Oct 09, 2026 00:00 UTC
-
Xenon gas and MRI: a new window into damaged lungs
Diagnosis Recruiting nowResearchers are testing whether MRI scans using inhaled xenon gas can reveal lung damage in people with cystic fibrosis and non-CF bronchiectasis earlier than standard breathing tests. The study includes children and adults with these conditions, plus healthy volunteers for compa…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Diagnosis
Last updated Oct 09, 2026 00:00 UTC
-
Can brain scans replace radiation to protect memory in lung cancer?
Prevention Recruiting nowResearchers are testing whether regular brain MRI scans alone can be as effective as prophylactic cranial irradiation (PCI) for people with small-cell lung cancer. PCI is used to prevent cancer from spreading to the brain, but it can cause cognitive problems. The trial compares o…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Prevention
Last updated Oct 18, 2026 00:00 UTC
-
Antibiotic combo tested to block secondary infections in sepsis
Prevention Recruiting nowResearchers are testing whether adding the antibiotic clarithromycin to standard antibiotic therapy can prevent new infections and secondary sepsis in adults hospitalized with community-acquired pneumonia and sepsis. The trial enrolls 252 adults who receive either clarithromycin …
Phase 3 • Sponsor: Hellenic Institute for the Study of Sepsis • Aim: Prevention
Last updated Oct 18, 2026 00:00 UTC
-
New nasal spray aims to stop colds and flu before they start
Prevention Recruiting nowThis study tests an investigational nasal spray called INNA-051 to see if it can safely prevent or reduce the severity of viral respiratory infections like colds and flu. It involves 1100 healthy adults aged 18 to 45 who are at higher risk due to their living or work conditions. …
Phase 2 • Sponsor: ENA Respiratory Pty Ltd • Aim: Prevention
Last updated Oct 18, 2026 00:00 UTC
-
Stem cells from umbilical cord tested against newborn lung disease
Prevention Recruiting nowBronchopulmonary dysplasia is a lung disease that affects babies born very early, keeping their lungs from developing properly. Researchers are testing mesenchymal stem cells taken from umbilical cord tissue in premature babies who weigh 1,250 grams or less and need a breathing m…
Phase 2 • Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal • Aim: Prevention
Last updated Oct 18, 2026 00:00 UTC
-
One-Shot flu prevention? new drug aims to protect High-Risk groups all season
Prevention Recruiting nowThis phase 3 trial is testing whether a single dose of CD388, a long-acting antiviral injection, can prevent the flu in 10,000 adults and teens at higher risk of complications. Participants receive either CD388 or a placebo and are monitored for flu-like illness over 24 weeks. Th…
Phase 3 • Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Prevention
Last updated Oct 17, 2026 00:00 UTC
-
Could a daily supplement keep the common cold at bay?
Prevention Recruiting nowThis trial tests whether a daily supplement called Immune X can help prevent common colds in healthy adults who often get upper respiratory infections. Over 16 weeks during winter, participants take either Immune X or a placebo and track any cold symptoms. The study compares how …
Sponsor: Givaudan France Naturals • Aim: Prevention
Last updated Oct 15, 2026 00:00 UTC
-
Bedside flu shot for heart patients: a simple strategy to save lives?
Prevention Recruiting nowThis trial tests whether offering a seasonal flu vaccine to heart patients while they are still in the hospital, along with active counseling, increases vaccination rates compared to counseling alone. The study enrolls adults hospitalized for acute coronary syndrome or heart fail…
Sponsor: Stephan Baldus • Aim: Prevention
Last updated Oct 15, 2026 00:00 UTC
-
New drug could shield preemie lungs from deadly disease
Prevention Recruiting nowThis study tests an investigational drug called zelpultide alfa to see if it can prevent bronchopulmonary dysplasia (BPD), a serious chronic lung disease, in extremely premature babies (born between 22 and 27 weeks). About 366 high-risk infants will receive either the drug or a p…
Phase 2/3 • Sponsor: Airway Therapeutics, Inc. • Aim: Prevention
Last updated Oct 11, 2026 00:00 UTC
-
Could a light device stop COVID and flu? new trial aims to find out.
Prevention Recruiting nowThis trial tests a handheld light device (RD-X19) to see if using it for 5 minutes every other day can prevent upper respiratory infections like COVID-19 and flu. It involves 130 military personnel and their families at a single base. Half will get the real device, half a sham de…
Sponsor: David Moss • Aim: Prevention
Last updated Oct 10, 2026 00:00 UTC
-
One shot to stop RSV: landmark trial for indigenous kids
Prevention Recruiting nowThis study tests whether a single dose of nirsevimab, an antibody that targets RSV, can prevent respiratory infections in Aboriginal and Torres Strait Islander children aged 6 months. Around 1,000 children will be randomly assigned to receive either the antibody or standard care.…
Phase 4 • Sponsor: Menzies School of Health Research • Aim: Prevention
Last updated Oct 09, 2026 00:00 UTC
-
Can High-Flow oxygen make bronchoscopy safer for failing lungs?
Symptom relief Recruiting nowResearchers are studying whether high-flow nasal cannula oxygen therapy helps patients with respiratory failure breathe safely during fiber-optic bronchoscopy, a procedure that threads a thin camera into the airways. The trial enrolls about 60 adults who need the procedure and al…
Sponsor: Mansoura University • Aim: Symptom relief
Last updated Oct 20, 2026 06:00 UTC
-
New lung master device aims to boost breathing in COPD and asthma patients
Symptom relief Recruiting nowThis study tests a device called the Lung Master, which is meant to increase lung capacity by practicing slow, deep breaths. Twenty adults with or without breathing conditions will use the device daily at home for one month. Researchers will measure lung function before and after…
Sponsor: University of Nebraska • Aim: Symptom relief
Last updated Oct 20, 2026 06:00 UTC
-
Can an anesthetic mist help asthma patients breathe easier?
Symptom relief Recruiting nowResearchers are testing whether adding a single dose of nebulized ketamine to standard asthma treatment helps adults with moderate to severe asthma attacks breathe better in the emergency department. Participants receive either the ketamine mist or a saltwater placebo mist, along…
Phase 2 • Sponsor: Oman Medical Speciality Board • Aim: Symptom relief
Last updated Oct 20, 2026 06:00 UTC
-
New breathing program aims to ease breathlessness in advanced lung cancer
Symptom relief Recruiting nowThis study tests a short behavioral program called BREEZE+ to help people with advanced lung cancer manage breathlessness. The program includes three nurse-led sessions and a digital app that teaches breathing and relaxation skills. Researchers will compare this to usual care in …
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Oct 20, 2026 06:00 UTC
-
New mask aims to make sleep apnea therapy easier to live with
Symptom relief Recruiting nowResearchers are testing the F&P Licorice mask, a device used with PAP or NIV breathing machines, in people who have obstructive sleep apnea or other chronic respiratory conditions. The study follows about 45 adults who already use this type of therapy at home. Over roughly two we…
Sponsor: Fisher and Paykel Healthcare • Aim: Symptom relief
Last updated Oct 18, 2026 00:00 UTC
-
Braids and conditioner may boost scalp cooling against chemo hair loss
Symptom relief Recruiting nowThis study tests whether special hairstyling methods — like braids, cornrows, or a conditioner-and-water mix — can help scalp cooling caps work better to prevent hair loss during chemotherapy. It focuses on people with curly or kinky hair (types 3 and 4), who have been underrepre…
Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Oct 18, 2026 00:00 UTC
-
Can laser light boost exercise gains in COPD?
Symptom relief Recruiting nowResearchers are testing whether photobiomodulation therapy, a treatment that uses superpulsed laser light on muscles, can improve functional capacity when added to a standard pulmonary rehabilitation program for people with COPD. The trial enrolls 20 patients with moderate-to-sev…
Sponsor: Federal University of Health Science of Porto Alegre • Aim: Symptom relief
Last updated Oct 18, 2026 00:00 UTC
-
Seaweed extract tested as chemo fatigue fighter
Symptom relief Recruiting nowThis study tests whether fucoidan, a supplement from brown seaweed, can prevent or reduce fatigue in people with gastrointestinal or gynecologic cancers who are starting chemotherapy. About 34 participants will receive either fucoidan or a placebo daily for up to 16 weeks. Resear…
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Oct 18, 2026 00:00 UTC
-
New lung valve registry aims to improve breathing in severe emphysema
Symptom relief Recruiting nowThis registry study is tracking 150 adults with severe emphysema who receive the Spiration Valve System, a one-way valve placed in the lung via a bronchoscope. The goal is to see if the device safely reduces shortness of breath and lung overinflation over 12 to 36 months. Partici…
Sponsor: Olympus Corporation of the Americas • Aim: Symptom relief
Last updated Oct 18, 2026 00:00 UTC
-
Can a buddy system ease the burden of a rare lung disease?
Symptom relief Recruiting nowThis study tests a 10-week program called RISE-HP for people with hypersensitivity pneumonitis (HP), a lung condition that can cause anxiety, depression, and poor quality of life. Participants work one-on-one with a trained peer coach (someone who also has HP) to learn coping ski…
Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Oct 18, 2026 00:00 UTC
-
New pill aims to shorten COPD Flare-Ups from common cold
Symptom relief Recruiting nowThis study tests an oral drug called vapendavir in 180 adults with COPD who catch a rhinovirus (common cold). The goal is to see if it can reduce the severity and length of breathing symptoms compared to a placebo. Participants are randomly assigned to one of two doses or a place…
Phase 2 • Sponsor: Altesa Biosciences, Inc. • Aim: Symptom relief
Last updated Oct 18, 2026 00:00 UTC
-
Smart scans aim to spare healthy lung during cancer radiation
Symptom relief Recruiting nowThis study tests whether using a lung perfusion PET/CT scan to guide radiation planning can reduce lung injury compared to standard anatomical planning. About 418 adults with lung tumors receiving stereotactic body radiotherapy (SBRT) will be randomly assigned to one of the two p…
Phase 3 • Sponsor: University Hospital, Brest • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
A pill to stop cancer treatment from stealing appetite?
Symptom relief Recruiting nowThis phase 3 trial tests whether megestrol acetate, a drug that stimulates appetite, can prevent weight loss in people with nasopharyngeal carcinoma undergoing chemoradiotherapy. Half of the 204 participants will take the drug daily for 11 weeks, and the other half will take a pl…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
Can a High-Tech Eye-Mask help you sleep better and use your CPAP more?
Symptom relief Recruiting nowThis study tests a wearable smart eye-mask that combines gentle heat and massage with voice-guided sleep therapy to help people who have both insomnia and sleep apnea. The 4-year project will first explore how the condition works, then develop the device, and finally test it in 1…
Sponsor: National Sun Yat-sen University • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
Can a Pre-Surgery boot camp keep lung cancer patients stronger through chemo?
Symptom relief Recruiting nowResearchers are testing whether a program of supervised exercise, nutritional guidance, and psychological support can protect cardiorespiratory fitness and lung function in people with locally advanced non-small cell lung cancer. The study enrolls 60 adults who receive chemothera…
Sponsor: Hospital Clinic of Barcelona • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
Vibrating breath tool tested to help COPD patients breathe easier after heart bypass
Symptom relief Recruiting nowResearchers test whether adding a flutter breathing device to standard chest physiotherapy helps COPD patients recovering from coronary artery bypass surgery. The flutter device creates vibrating pressure as a person breathes out, which may help loosen and clear mucus. The trial …
Sponsor: Foundation University Islamabad • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
New formula could offer safe option for Milk-Allergic babies
Symptom relief Recruiting nowThis study tests whether a special hypoallergenic baby formula is safe for infants and children with cow's milk allergy. About 61 children will try the formula in a controlled setting, then drink it at home for a week. Researchers will watch for allergic reactions and track how m…
Sponsor: Abbott Nutrition • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
Could a higher dose of a common seizure drug better protect newborn brains?
Symptom relief Recruiting nowThis study tests whether a higher-than-usual dose of the seizure medicine levetiracetam can safely stop seizures in newborns. About 133 full-term infants with seizures will first receive a standard dose, and if seizures continue, they will be randomly assigned to get either a hig…
Phase 2 • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
Can a slower breathing rhythm help COPD patients breathe easier?
Symptom relief Recruiting nowResearchers are testing whether coherent breathing, a slow, steady breathing pattern, eases breathlessness and improves lung function better than regular paced breathing in people with mild to moderate COPD. Participants attend supervised sessions twice a week for four weeks whil…
Sponsor: Foundation University Islamabad • Aim: Symptom relief
Last updated Oct 17, 2026 00:00 UTC
-
New lozenge aims to ease radiation mouth sores for hours
Symptom relief Recruiting nowThis phase 3 trial tests whether a lozenge called BupiZenge, which contains the long-acting painkiller bupivacaine, can relieve mouth pain from radiation therapy better than the standard lidocaine rinse. About 150 adults with head and neck cancer will be randomly assigned to one …
Phase 3 • Sponsor: OncoZenge AB • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
New MRI technique aims to spare saliva glands during cancer radiation
Symptom relief Recruiting nowThis Phase 2 trial tests whether using MRI to map saliva ducts before radiation therapy can reduce dry mouth in people with oropharyngeal cancer. About 98 participants will be randomly assigned to standard radiation planning or a new approach that spares the parotid ducts. The ma…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
New online program aims to tackle postpartum depression
Symptom relief Recruiting nowThis study tests a virtual platform called MOVIN that helps pregnant and postpartum people with depression or anxiety. Participants get a care coordinator who recommends online treatments and works with their doctor. The goal is to see if this approach reduces symptoms better tha…
Sponsor: Women's College Hospital • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
New adaptive palliative care model aims to give right care at the right time
Symptom relief Recruiting nowThis study tests a home-based palliative care program called TIER-PC that adjusts the care team based on a patient's symptoms and ability to function. It includes 60 adults with advanced heart failure or certain cancers living in Manhattan. The program adds more specialists—like …
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Could a painkiller stop the cough that Won't quit in lung fibrosis?
Symptom relief Recruiting nowThis study tests whether an extended-release form of nalbuphine, a pain medication, can safely reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a lung scarring disease. About 306 adults with IPF and a cough lasting at least 8 weeks will receive either t…
Phase 3 • Sponsor: Trevi Therapeutics • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Monthly shot aims to quiet sleep apnea and shed pounds
Symptom relief Recruiting nowResearchers are testing whether a monthly injection of berobenatide can reduce the severity of obstructive sleep apnea and lower body weight in adults who have overweight or obesity and use a PAP breathing machine. The trial enrolls about 258 adults with moderate to severe sleep …
Phase 3 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Gamified workouts before bed may ease sleep apnea
Symptom relief Recruiting nowThis study tests a digital, game-like exercise system called ApneaTheraPlay for people with obstructive sleep apnea. Participants will do a mix of breathing, aerobic, strengthening, and throat exercises three times a week for 12 weeks, either through the game or a structured prog…
Sponsor: Medipol University • Aim: Symptom relief
Last updated Oct 15, 2026 00:00 UTC
-
Lung cancer patients may skip hospital stays with new home monitoring program
Symptom relief Recruiting nowThis study tests a Hospital-at-Home program for people with small cell lung cancer receiving tarlatamab. The goal is to see if monitoring patients at home using telemedicine is as safe and effective as keeping them in the hospital after treatment. About 70 adults will take part, …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Opioid-Based pill tested against the relentless cough of lung fibrosis
Symptom relief Recruiting nowPeople with idiopathic pulmonary fibrosis often develop a chronic cough that no approved treatment targets. This Phase 3 trial tests nalbuphine extended-release tablets, an opioid-related medicine, against placebo in about 200 adults with the condition. Over 12 weeks, researchers…
Phase 3 • Sponsor: Trevi Therapeutics • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Cancer injection satisfaction study recruits 700 patients
Symptom relief Recruiting nowThis study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …
Sponsor: Hoffmann-La Roche • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
New shoulder block may spare your diaphragm
Symptom relief Recruiting nowThis study tests two types of nerve blocks for shoulder surgery to see which one is less likely to temporarily paralyze the diaphragm, the main muscle for breathing. About 70 adults having elective shoulder surgery will be randomly assigned to receive either a standard interscale…
Sponsor: Marmara University • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
Can breathing devices keep ventilator patients stronger?
Symptom relief Recruiting nowResearchers test two breathing devices in patients with restrictive lung disease who need a ventilator in the ICU. One device trains the inspiratory muscles at a set resistance, and the other adds positive expiratory pressure to help clear secretions. The trial measures lung comp…
Sponsor: Foundation University Islamabad • Aim: Symptom relief
Last updated Oct 11, 2026 00:00 UTC
-
COPD study tests two education programs to keep patients out of hospital
Symptom relief Recruiting nowThis study compares two COPD self-management education programs: a self-guided booklet and a counselor-led phone program. Researchers want to see which approach better reduces hospitalizations and improves quality of life. 448 adults with COPD who have been hospitalized in the pa…
Sponsor: Rush University Medical Center • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
New drug aims to cut short sickle cell pain attacks
Symptom relief Recruiting nowThis study tests an investigational drug called CSL889 in 70 adults and adolescents with sickle cell disease who are having a painful vaso-occlusive crisis. The goal is to see if the drug can safely shorten the crisis and reduce the need for strong pain medicines. Participants wi…
Phase 2 • Sponsor: CSL Behring • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
New oxygen device aims to ease breathing at home for chronically ill patients
Symptom relief Recruiting nowThis study tests whether a new type of home oxygen therapy, called high-flow nasal cannula (HFNC), can improve breathing comfort and quality of life for people with long-term lung or heart conditions. Participants will try both HFNC and standard oxygen therapy for two weeks each …
Sponsor: Università degli Studi di Ferrara • Aim: Symptom relief
Last updated Oct 10, 2026 00:00 UTC
-
Phlegm test could finally silence chronic cough in lung patients
Symptom relief Recruiting nowThis study tests whether analyzing a patient's phlegm can help doctors choose better treatments for chronic cough in interstitial lung disease (ILD). About 120 adults with ILD and daily cough for at least 8 weeks will be randomly assigned to either phlegm-guided treatment or stan…
Sponsor: McMaster University • Aim: Symptom relief
Last updated Oct 09, 2026 00:00 UTC
-
New therapy aims to ease emotional toll of advanced lung cancer
Symptom relief Recruiting nowThis study tests a program called LiveWell, which teaches emotional coping skills to people with metastatic lung cancer who are feeling anxious or depressed. About 80 participants will either take the program or receive usual care. The goal is to see if the program is practical, …
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Oct 09, 2026 00:00 UTC
-
New imaging agent may help doctors see which lung tumors are still growing during immunotherapy
Knowledge-focused Recruiting nowThis early-phase trial will test a new PET imaging agent called 64Cu-DOTA-pembrolizumab in 6 people with stage IV non-small cell lung cancer who are already on the immunotherapy drug pembrolizumab. The goal is to see if the imaging agent can safely tell the difference between tum…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
New study targets lung cancer in the young: what makes it different?
Knowledge-focused Recruiting nowThis study aims to learn more about lung cancer in adults diagnosed at age 45 or younger. Researchers will collect blood samples and medical information from 500 participants to study the biology of these cancers and look for genetic changes that could lead to better treatments. …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
Does oktoberfest fuel the spread of respiratory viruses?
Knowledge-focused Recruiting nowThe MunichFlu study investigates whether attending the Munich Oktoberfest, one of the world's largest mass gatherings, is linked to respiratory viral infections. Researchers recruit adults at the festival and follow up one to two weeks later with an online questionnaire about sym…
Sponsor: LMU Klinikum • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
Could a spirometer test guide breathing support in respiratory failure?
Knowledge-focused Recruiting nowThis study looks at whether the amount of air a person breathes in on their own matches the amount they breathe when using a non-invasive ventilation (NIV) mask. It involves 30 adults with acute respiratory failure who are in intensive care. Researchers will measure tidal volume …
Sponsor: Centre Hospitalier Departemental Vendee • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
Smart sensors aim to predict dangerous COPD attacks before they happen
Knowledge-focused Recruiting nowThis study follows 250 adults with severe COPD who use a breathing machine at home. Researchers collect data from sensors and regular check-ups to build a model that can warn of an upcoming flare-up. The goal is to catch problems early and reduce hospital visits.
Sponsor: Beijing Chao Yang Hospital • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
Can a new tool predict when duchenne patients will need breathing help?
Knowledge-focused Recruiting nowDuchenne muscular dystrophy weakens muscles over time, including the muscles that control breathing, and adults with the condition face a rising risk of lung problems and breathing failure. This study follows about 150 adults with genetically confirmed Duchenne across 13 Italian …
Sponsor: Istituto Giannina Gaslini • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
Sinus polyps: scientists hunt for chemical clues in tissue and blood
Knowledge-focused Recruiting nowChronic rhinosinusitis with nasal polyps is a long-term inflammatory condition of the nose and sinuses, and researchers do not fully understand what drives it. This study compares nasal tissue and blood samples from 80 people, some with nasal polyps and some without. The team mea…
Sponsor: Harran University • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
Does sleep apnea surgery harm swallowing? researchers track oral function
Knowledge-focused Recruiting nowPeople with obstructive sleep apnea often report trouble swallowing, especially after upper-airway surgery, but researchers do not know how surgery affects swallowing and oral function over time. This study follows adults with moderate-to-severe sleep apnea who choose their own t…
Sponsor: National Sun Yat-sen University • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
New CF drug candidate VX-581 begins first human safety tests
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug called VX-581 in 128 healthy volunteers to see if it is safe and how the body processes it. The study is double-blind and placebo-controlled, meaning some participants get the drug and some get a dummy pill. This is a first step toward…
Phase 1 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Knowledge-focused
Last updated Oct 20, 2026 06:00 UTC
-
Massive study aims to unlock mysteries of rare blood vessel disease
Knowledge-focused Recruiting nowThis study follows up to 4,000 people with vasculitis (a group of diseases that cause blood vessel inflammation) and healthy volunteers over many years. Researchers collect blood, urine, imaging, and genetic samples to learn how the disease develops and changes. The goal is to fi…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Researchers launch major tissue bank to unlock secrets of mesothelioma
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Cancer samples sought to unlock treatment secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Gene therapy patients monitored for 15 years in safety Follow-Up
Knowledge-focused Recruiting nowThis study provides long-term follow-up for people who previously received gene therapy or other immunotherapy for cancers like prostate, liver, breast, colon, or lung cancer. Participants will have annual health check-ups or phone calls for up to 15 years to monitor for any long…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Healthy volunteers willingly catch the flu for science
Knowledge-focused Recruiting nowThis study aims to find the safest and most effective dose of a specific flu virus to give to healthy adults in a controlled setting. About 90 volunteers aged 18 to 55 will be exposed to the virus or a placebo and closely monitored. The goal is to create a reliable model for test…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists probe immune System's role in chronic disease
Knowledge-focused Recruiting nowThis study looks at how the body's innate immune system responds to certain environmental exposures by measuring inflammation markers in blood. Researchers will collect blood samples from up to 725 healthy volunteers aged 18-45 to analyze how specific genes and proteins react. Th…
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Cancer genetics study aims to personalize treatment
Knowledge-focused Recruiting nowThis study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Can blood and tissue tests predict who beats lung cancer before surgery?
Knowledge-focused Recruiting nowResearchers at Yonsei University are studying whether tests on tumor tissue and blood can predict how well patients with stage IB-III non-small cell lung cancer respond to chemotherapy plus immunotherapy given before surgery. About 300 patients will receive standard neoadjuvant c…
Sponsor: Yonsei University • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Blood tests may guide better lung cancer treatment choices
Knowledge-focused Recruiting nowThis study looks at blood and tissue samples from people with advanced non-small cell lung cancer to find markers that predict how well immunotherapy works. The goal is to use these markers to choose the best second-line treatment if the first one stops working. About 535 partici…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
400 asthma patients tracked for 5 years to uncover environmental triggers
Knowledge-focused Recruiting nowThis study follows 400 adults aged 18–60 with moderate-to-severe asthma for up to 5 years. Researchers collect blood, urine, stool, dust, saliva, and lung samples at regular visits to see how bacteria and other environmental factors affect asthma symptoms and flare-ups. The goal …
Sponsor: National Institute of Environmental Health Sciences (NIEHS) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists launch major study to unravel mysteries of rare lung infections
Knowledge-focused Recruiting nowThis study aims to learn more about non-tuberculous mycobacterial (NTM) infections, which cause repeated lung and other organ infections. Researchers will study up to 1,000 participants to understand the genetics, symptoms, and best treatments for these infections. The study also…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Brazil launches major study to track severe COPD outcomes
Knowledge-focused Recruiting nowThis study will follow 693 people in Brazil with severe or very severe COPD to track how often they are hospitalized, have flare-ups, or die. Researchers want to understand the real-world impact of the disease in this group. No new treatments are being tested—only data is collect…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists collect tissue to unlock lung cancer secrets
Knowledge-focused Recruiting nowThis study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Rare cancer syndrome under the microscope: what families need to know
Knowledge-focused Recruiting nowThis study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists launch massive tissue collection to unlock secrets of head and neck diseases
Knowledge-focused Recruiting nowThis study aims to create a large collection of tissue samples from people with head and neck disorders, such as hearing loss, mouth diseases, and throat cancers. Researchers will use leftover surgical tissue and additional samples like blood, saliva, and cheek swabs to study the…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Why do lung cancer patients quit a key drug? new study seeks answers
Knowledge-focused Recruiting nowThis study interviews about 85 patients with early-stage non-small cell lung cancer and 15 doctors to find out what makes it hard or easy to keep taking the drug osimertinib after surgery. The goal is to identify barriers like side effects, cost, or communication issues, and faci…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Rare gene study aims to unlock kidney cancer risks
Knowledge-focused Recruiting nowThis study looks at a rare inherited condition called Birt-Hogg-Dube (BHD) syndrome, which raises the risk of kidney cancer. Researchers will collect blood, saliva, and tissue samples from up to 950 participants to find the genes involved and understand how kidney tumors grow. Th…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Can a custom toolkit help indigenous smokers spot lung cancer earlier?
Knowledge-focused Recruiting nowThis study tests whether a specially designed educational toolkit, called the Lung Toolkit, can improve knowledge about lung cancer and screening among American Indian and Alaskan Native adults aged 50 to 80 who smoke cigarettes. The toolkit includes a website with resources and …
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists dive deep into the roots of a mysterious lung disease
Knowledge-focused Recruiting nowThis study aims to understand how lymphangioleiomyomatosis (LAM) damages the lungs at the cellular and genetic level. Researchers will follow up to 2,000 participants, including women with LAM and healthy volunteers, using advanced imaging and lab tests. The goal is to find the p…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
No treatment, just samples: new study aims to understand cancer immunity
Knowledge-focused Recruiting nowThis study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
Scientists hunt for lung disease genes in 3,500 volunteers
Knowledge-focused Recruiting nowThis study looks at how genes play a role in lung diseases like cystic fibrosis, asthma, and pulmonary fibrosis. Researchers will examine DNA from up to 3,500 people with and without lung disease to find genetic differences. The goal is to better understand what causes these cond…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Oct 18, 2026 00:00 UTC
-
New breathing technique could help critically ill kids on ventilators
Knowledge-focused Recruiting nowThis study tests whether a personalized lung volume optimization maneuver can improve heart and lung function in children on ventilators. It includes two groups: children recovering from heart surgery and those with severe respiratory failure. Researchers will adjust ventilator p…
Phase 1/2 • Sponsor: Charite University, Berlin, Germany • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Scientists launch Long-Term study to unravel mysterious liver disease
Knowledge-focused Recruiting nowThis study is observing 400 people aged 12 and older who have noncirrhotic portal hypertension (NCPH) or are at risk for it. NCPH is a liver condition that increases blood pressure in the liver's blood vessels without causing cirrhosis, and often has no early symptoms. Researcher…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
Knowledge-focused Recruiting nowThis study is tracking how the cancer drug tislelizumab is actually used in everyday European clinics for patients with advanced non-small cell or small cell lung cancer. Researchers will observe 440 participants to see treatment patterns, dosing changes, and real-world outcomes …
Sponsor: BeOne Medicines • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Pilot study to test best ventilator approach for severe lung failure
Knowledge-focused Recruiting nowThis pilot study will enroll 80 ICU patients with acute hypoxemic respiratory failure to compare two ventilator strategies: one that allows patients to breathe spontaneously and one that fully controls their breathing. The goal is to see if a larger trial is possible and to gathe…
Sponsor: Oslo University Hospital • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Scientists hunt for genetic clues in lung and esophageal cancers
Knowledge-focused Recruiting nowThis study aims to collect tumor, normal tissue, and blood samples from up to 1559 people with cancers of the lung, esophagus, or pleura. Researchers will analyze genetic and epigenetic changes to better understand these diseases and identify potential markers for future treatmen…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Yearly lung tests may reveal which children face worse Long-Term outcomes
Knowledge-focused Recruiting nowResearchers at Odense University Hospital are studying children with severe lung disease to understand how their condition changes over time. About 200 participants will have their lung function measured once a year using several different methods. The goal is to find early signs…
Sponsor: Odense University Hospital • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
10,000 volunteers needed to unlock allergy mysteries
Knowledge-focused Recruiting nowThis study aims to collect blood, nasal fluid, skin cells, urine, and medical data from 10,000 people aged 3 to 100 with allergies, asthma, eczema, or sinus issues. Participants will have up to 3 years of follow-up visits and questionnaires. The goal is to create a large reposito…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Oct 17, 2026 00:00 UTC
-
Brain scans may predict who needs a breathing tube
Knowledge-focused Recruiting nowThis study looks at how the brain and lungs communicate in patients with severe breathing failure who are getting high-flow oxygen. Researchers will use brain wave monitors (EEG), oxygen sensors (NIRS), and muscle activity sensors (EMG) before and after starting oxygen therapy. T…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
New imaging trial peers inside tumors to track experimental Drug's path
Knowledge-focused Recruiting nowThis study uses a special PET scan to see how the experimental drug BI 764532 travels through the body and reaches tumors. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers who have run out of standard treatment options. The main goal is to mea…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
Can Drug-Level testing personalize cystic fibrosis treatment?
Knowledge-focused Recruiting nowResearchers are studying how the cystic fibrosis drugs elexacaftor, tezacaftor and ivacaftor move through the body. The trial enrolls people aged 6 and older with cystic fibrosis who carry at least one F508del mutation and already take this drug combination. Participants keep the…
Phase 4 • Sponsor: Istituto Giannina Gaslini • Aim: Knowledge-focused
Last updated Oct 16, 2026 00:00 UTC
-
Scientists hunt for protein clues to Pneumonia's hidden causes
Knowledge-focused Recruiting nowThis study looks at proteins in lung fluid from 750 people with pneumonia to find biomarkers that could reveal what's causing the lung inflammation. Participants undergo a standard bronchoscopy with lung washings, plus a blood draw. The goal is to better understand different type…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Scientists scour lungs for clues to why some get infections
Knowledge-focused Recruiting nowThis study gathers fluid and tissue from the lungs and nose of healthy volunteers and people with a history of lung infections. Researchers will compare samples to find differences in immune function that might explain why some people are more prone to infections. Participants un…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
New study aims to crack the code on Hard-to-Treat sleep apnea in heart failure
Knowledge-focused Recruiting nowThis study looks at why people with heart failure or those taking opioid painkillers develop central sleep apnea (pauses in breathing during sleep). Current treatments don't work well, so researchers will test combinations of breathing machines and medications in 200 Veterans. Th…
Phase 4 • Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Scientists launch deep dive into rare bleeding and lung disease
Knowledge-focused Recruiting nowThis study aims to learn more about Hermansky-Pudlak Syndrome (HPS), a rare inherited disease that causes light skin/eye color, bleeding problems, and often deadly lung scarring. Researchers will follow 600 people with HPS and their family members to track how the disease progres…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Can CPAP for sleep apnea boost cellular energy in women with PMOS?
Knowledge-focused Recruiting nowResearchers at the University of Chicago are studying how obstructive sleep apnea affects mitochondrial function and cellular metabolism in women with Polyendocrine Metabolic Ovarian Syndrome (PMOS). Ten women aged 18 to 40 with PMOS and sleep apnea will receive two nights of CPA…
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Lung cancer rehab study aims to pinpoint what really matters for patients
Knowledge-focused Recruiting nowThis study will enroll 63 people with advanced non-small cell lung cancer whose disease has been stable for at least 6 months. Participants will take part in a 3-month rehabilitation program that includes physical activity. Researchers will measure quality of life, hand grip stre…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Oct 15, 2026 00:00 UTC
-
Asthma under the microscope: 2,500 patients enrolled in landmark Real-World study
Knowledge-focused Recruiting nowThis study is observing 2,500 people with asthma to learn more about their symptoms, treatments, and quality of life in everyday settings. Participants will fill out surveys and may provide blood samples or lung function tests. The goal is to better understand how asthma affects …
Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Lung cancer care under the microscope: how testing shapes treatment
Knowledge-focused Recruiting nowResearchers in Germany run a large observational platform to see how doctors test lung tumors for molecular markers and choose treatments for patients with non-small cell and small cell lung cancer. The study follows adults across all cancer stages, collecting details on biomarke…
Sponsor: AIO-Studien-gGmbH • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Tiny lung cells may hold key to early detection of deadly transplant complication
Knowledge-focused Recruiting nowThis study looks at abnormal cells in the lungs of 15 people who developed bronchiolitis obliterans syndrome after a stem cell or lung transplant. Researchers want to understand these cells better so doctors can spot the disease earlier in future patients. Participants will have …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Lung tumor treatment under the microscope: new registry launched
Knowledge-focused Recruiting nowThis study is a registry that gathers information from 250 people with lung cancer or cancer that has spread to the lungs. Participants will have their tumors treated with a robotic scope inserted through the mouth to burn the tumor. The goal is to learn how well this procedure w…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Home devices may spot lung flare-ups before they become emergencies
Knowledge-focused Recruiting nowThis study tests whether people with fibrotic interstitial lung disease can use home monitoring devices—like a spirometer, pulse oximeter, and scale—to help detect serious lung events such as flare-ups or hospitalizations. About 200 participants will use these devices connected t…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Lung cancer patients and doctors share what drives their treatment choices
Knowledge-focused Recruiting nowThis study uses surveys to understand what factors influence Chinese patients and doctors when selecting first-line EGFR-TKI therapy for advanced non-small cell lung cancer. Researchers will ask about preferences for treatment benefits, side effects, and other attributes. The goa…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Robotic lung biopsy system under Real-World scrutiny
Knowledge-focused Recruiting nowThis study is observing how well the Ion endoluminal system, a robotic tool, works for lung nodule biopsies and localization in everyday medical practice across Europe. Researchers will track 1,200 adults to see how often the tool correctly diagnoses lung nodules and how often co…
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Scientists hunt for cancer clues in blood, urine, and bone marrow
Knowledge-focused Recruiting nowThis study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…
Sponsor: University of Missouri-Columbia • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Brain scans reveal secrets of lost smell
Knowledge-focused Recruiting nowThis study tracks 80 adults with different smell disorders (like total loss, partial loss, or distorted smell) plus healthy volunteers over one year. Researchers use brain scans, smell tests, and questionnaires to see how the brain changes and how smell loss impacts mood and dail…
Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD) • Aim: Knowledge-focused
Last updated Oct 11, 2026 00:00 UTC
-
Scientists launch major study to unravel salivary gland mysteries
Knowledge-focused Recruiting nowThis study aims to learn more about diseases that affect the salivary glands, which produce saliva. Researchers will collect medical data, blood, saliva, and tissue samples from people with these conditions, their relatives, and healthy volunteers. The goal is to better understan…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
New model predicts oxygen therapy failure in just 30 minutes
Knowledge-focused Recruiting nowThis study aimed to predict whether high-flow nasal oxygen therapy would fail within 30 minutes for patients with acute respiratory failure. Researchers used data from 164 participants, including a special imaging technique called electrical impedance tomography, to build a predi…
Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
NCI opens screening study for experimental cell therapies in multiple cancers
Knowledge-focused Recruiting nowThis study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
New study explores why cancer patients lose their appetite
Knowledge-focused Recruiting nowThis study looks at how cancer and its treatments change a person's sense of taste and smell, and how that affects their eating and nutrition. Researchers will follow 306 people newly diagnosed with cancer of the mouth, throat, colon, or liver. They will use questionnaires, taste…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Can a simple questionnaire improve sleep apnea treatment?
Knowledge-focused Recruiting nowThis study tests whether a new questionnaire called PLATO can help dentists track how well oral appliance therapy works for people with obstructive sleep apnea. The questionnaire, developed by the American Academy of Sleep Medicine, measures patient-reported outcomes. Researchers…
Sponsor: Nevada Dental Sleep • Aim: Knowledge-focused
Last updated Oct 10, 2026 00:00 UTC
-
Empathy training for cancer doctors aims to erase lung cancer stigma
Knowledge-focused Recruiting nowThis study tests whether a special training program can help cancer doctors communicate more empathetically with lung cancer patients. Many lung cancer patients feel judged or stigmatized during medical visits, which can harm their well-being and care. The training teaches doctor…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Why sepsis hits some patients harder: 6,000-Person study hunts for answers
Knowledge-focused Recruiting nowSepsis and acute respiratory distress syndrome (ARDS) can look very different from one patient to the next, and doctors lack reliable ways to predict who will recover. This observational study follows 6,000 adults with sepsis, ARDS, or both at hospitals across China. Researchers …
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Can a simple questionnaire help lung cancer patients make better decisions?
Knowledge-focused Recruiting nowThis study tests whether a new screening tool can help people with advanced lung cancer better understand their illness and treatment goals. About 100 patients will either use the tool or receive usual care. The goal is to see if the tool leads to more informed decisions that mat…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
Knowledge-focused Recruiting nowThis trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Fitbit study tracks lung cancer Patients' steps to improve surgery recovery
Knowledge-focused Recruiting nowThis study looks at how walking and sleep habits affect recovery in people having lung cancer surgery. About 240 patients will wear a Fitbit to track their steps and sleep, and some will get extra support to increase walking. The goal is to see if more walking leads to fewer comp…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Can cannabis ease cancer symptoms? 2,000 patients join study
Knowledge-focused Recruiting nowThis study follows 2,000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps with symptoms like pain or nausea over time. No treatme…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
New study tracks hidden struggles of rare head and neck cancer survivors
Knowledge-focused Recruiting nowThis study follows 300 people treated for sinonasal, nasopharyngeal, or skull base tumors to track their symptoms and functional changes over time. Participants will complete symptom questionnaires and undergo standard tests like hearing, eye, and speech exams. The goal is to lea…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
New study tracks health of parents with cystic fibrosis
Knowledge-focused Recruiting nowThis study follows 146 people with cystic fibrosis who recently became first-time parents. Researchers will track their lung function, mental health, and stress levels over five years using surveys and medical records. The goal is to understand how parenthood affects their health…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
New strategy aims to prevent breathing trouble after hernia repair
Knowledge-focused Recruiting nowThis study looks at a new way to close the belly wall during large hernia surgery to prevent breathing problems right after the operation. Doctors will use standard breathing measurements during surgery to decide the best closure method. The study will include 50 adults who are a…
Sponsor: Swissmed Hospital • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Smartwatches tested to monitor kids on antibiotics
Knowledge-focused Recruiting nowThis study looks at how families feel about antibiotic use and whether a Garmin smartwatch can track symptoms in children aged 4-17 with common infections like UTIs, tonsillitis, or skin infections. About 300 children from the Royal Children's Hospital Emergency Department will w…
Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Hunting hidden DNA clues in lung cancer
Knowledge-focused Recruiting nowResearchers at Massachusetts General Hospital are studying blood and tissue samples from people with newly diagnosed primary lung cancer. The goal is to understand what changes occur in DNA and whether certain genetic patterns, called metabolic polymorphisms, differ among lung ca…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
Hunting the DNA that shapes lung cancer risk and survival
Knowledge-focused Recruiting nowResearchers at Massachusetts General Hospital are studying how genes affect lung cancer risk and survival. The study compares people who have lung cancer with people who do not, using DNA samples and health records. They look for small genetic differences linked to who develops t…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Oct 09, 2026 00:00 UTC
-
What shields kids from flu? scientists track blood and nose immunity
Knowledge-focused Recruiting nowResearchers follow 150 healthy children aged 2 to 5 in South Africa through a flu season to see how immune responses in blood and the nose relate to protection against influenza. Nurses collect nasal swabs three times a week and blood samples before, during, and after the season.…
Sponsor: National Institute for Communicable Diseases, South Africa • Aim: Knowledge-focused
Last updated Oct 08, 2026 00:00 UTC
-
Could a sticky patch replace invasive temperature probes in newborns?
Knowledge-focused Recruiting nowThis pilot study is testing whether a wireless adhesive thermometer can safely and accurately monitor body temperature in newborns undergoing therapeutic hypothermia, a cooling treatment for brain injury. Currently, temperature is tracked with an invasive rectal probe, which carr…
Sponsor: Medical University of Graz • Aim: Knowledge-focused
Last updated Oct 08, 2026 00:00 UTC